

1 **Development of $\gamma\delta$ T cells in the thymus – a human perspective**

2
3 Lena Boehme ^a, Juliette Roels ^{a,b,c}, Tom Taghon ^{a,c}

4
5 ^aDepartment of Diagnostic Sciences, Ghent University, Ghent, Belgium

6 ^bDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium

7 ^cCancer Research Institute Ghent (CRIG), Ghent, Belgium

8
9 Corresponding author: Prof. Tom Taghon (tom.taghon@ugent.be)

10 11 12 **Abstract**

13 $\gamma\delta$ T cells are increasingly emerging as crucial immune regulators that can take on innate and
14 adaptive roles in the defence against pathogens. Although they arise within the thymus from
15 the same hematopoietic precursors as conventional $\alpha\beta$ T cells, the development of $\gamma\delta$ T cells
16 is less well understood. In this review, we focus on summarising the current state of
17 knowledge about the cellular and molecular processes involved in the generation of $\gamma\delta$ T cells
18 in human.

19 20 **Keywords**

21 $\gamma\delta$ T cells, T cell development, lineage commitment, human, thymocyte, thymus

25 **1 Introduction**

26

27 Like other unconventional T cells, $\gamma\delta$ T cells seem to combine both innate and adaptive
28 characteristics in their phenotype and behaviour. The $\gamma\delta$ T cell receptor (TCR) is generated
29 through somatic gene rearrangements and exhibits junctional diversity similar to the $\alpha\beta$ TCR;
30 however, the overall $\gamma\delta$ TCR repertoire is restricted and its functionality appears to resemble
31 that of a pattern recognition receptor [1]. Moreover, $\gamma\delta$ T cells display rapid responses to
32 pathogen encounters without the need for extensive proliferation and effector differentiation.
33 In contrast to conventional $\alpha\beta$ T cells, $\gamma\delta$ T cells can recognise unprocessed peptide antigens
34 but also a range of different non-peptide antigens such as lipids and phosphoantigens from
35 exogenous and endogenous sources [2,3]. Their ability to respond to tumour-derived antigens
36 and their cytolytic capacities, in combination with their lack of HLA restriction, has made
37 them attractive tools for cancer immunotherapy [4–6]. Most clinical studies to date have
38 focussed on *ex vivo* expansion or *in vivo* activation of mature $\gamma\delta$ T cells [4,7] but these
39 approaches come with several limitations, such as T cell exhaustion. Instead, *de novo*
40 generation of $\gamma\delta$ T cells, for instance from induced pluripotent stem cells (iPSCs), holds great
41 promise to overcome these issues and may be suited to address the need for off-the-shelf
42 therapies [8–10]. To further develop these technologies, a detailed understanding of human
43 $\gamma\delta$ T cell differentiation and maturation is crucial. Many exceptional reviews on the
44 development of $\gamma\delta$ T cells in the mouse thymus have been published [11–20], however,
45 insights into this process in the human context are still more limited. This gap is not
46 surprising given the experimental limitations in studying human samples and the elegant
47 ways in which mouse models and perturbation approaches have been able to advance the
48 field. Nevertheless, there is ample evidence of prominent differences between human and
49 mouse $\gamma\delta$ T cell development (Table 1), which has direct and critical consequences for
50 translational work. For this reason, we use this review to specifically discuss the current state
51 of knowledge with regard to the establishment of $\gamma\delta$ T cells in the human thymus.

52

53

54 **2 Early development of bipotent T cell progenitors in the thymus**

55

56 The regulatory intricacies of early T cell development, during which thymus immigrating
57 multipotent precursors undergo sequential T lineage specification and commitment, apply to
58 all conventional T cells as well as the unconventional T cell subsets discussed in this issue
59 and have been reviewed extensively in mouse [21–27] and human [28–31]. Nevertheless, we
60 will provide a brief overview of the earliest stages of T cell development in the human
61 thymus.

62

63 **2.1 Commitment to the T lineage**

64 Although their differentiation and maturation takes place in the thymus, all T cells develop
65 from hematopoietic stem and progenitor cells (HSPCs) that originate from the bone marrow
66 or fetal liver. These HSPCs migrate to and colonise the thymus as multipotent thymus
67 seeding progenitors (TSPs), that then rely on the thymic microenvironment to direct their
68 complex and gradual differentiation into a broad range of different T cell subsets (Figure 1).

69 Human HSPCs and TSPs not only possess T lineage potential but can also develop into
70 Natural Killer (NK) cells and Dendritic Cells (DC), as well as other lineages under
71 permissive culture conditions *in vitro* [32–36]. As a result of their engagement with Notch
72 ligands expressed on thymic epithelial cells (TECs), TSPs experience Notch signalling,
73 which leads to progression to the early T cell precursor (ETP) stage and upregulation of
74 genes with essential roles in T lineage development, such as *GATA3* [37] and IL7 receptor
75 (*IL7R*) [38,39]. ETPs already exhibit a reduced potential to develop into other hematopoietic
76 lineages [39–41] and the transcription factors *BCL11B* and *GATA3* subsequently further
77 extinguish non-T lineage potential by suppressing alternative cell fates and inducing the T
78 lineage transcriptional programme [34,42] (Figure 2A). Upregulation of CD1 on the cell
79 surface marks the irreversible commitment of thymocytes to the T lineage, although loss of
80 CD44 has recently been identified as a more precise marker of this developmental milestone
81 [43]. Induction of IL7R signalling via TEC-derived IL7 is then thought to promote
82 proliferation and survival of T lineage cells [39,44] and thereby represents another essential
83 driver of early T cell development as shown by the prominent lack of T cells that IL7R-
84 deficient patients present with [45]. Following T lineage commitment, cells are often referred
85 to as bipotent precursors to denote their ability to differentiate into $\alpha\beta$ and $\gamma\delta$ lineage T cells
86 but lack of non-T lineage potential.

87

88 **2.2 Rearrangement of the T cell receptor loci**

89 Generation of a diverse TCR repertoire is achieved through V(D)J recombination of the four
90 TCR loci, which takes place in the CD34+ stages for *TRB*, *TRG* and *TRD*, and later in the
91 double positive (DP, CD4+CD8+) stage for *TRA* (Figure 1). Immature thymocytes that
92 successfully rearrange their *TRG* and *TRD* loci and are thus able to assemble a functional $\gamma\delta$
93 TCR, can commit to the $\gamma\delta$ lineage, whereas an in-frame rearrangement of the β -chain allows
94 the generation of a pre-TCR, which drives cells through β -selection and towards the $\alpha\beta$
95 lineage. Rearrangement of the TCR loci is initiated already prior to T lineage commitment
96 since expression of RAG and initial *TRD* rearrangements have been observed at the
97 CD34+CD1- stage [32,46–48]. Importantly, the rearrangements do not preclude alternative
98 fates as these cells can still be directed towards myeloid and erythroid lineages *in vitro* [32].
99 Rearrangement of the *TRG* and *TRB* loci is only fully initiated after T lineage commitment
100 [43,46–48], whereby in-frame *TRB* rearrangements seem to arise mainly at the immature
101 single positive (ISP) stage [46]. In fact, several studies point towards a late onset of *TRB*
102 recombination: Rearranged *TRG* loci were observed in the majority of peripheral $\alpha\beta$ T cells
103 and $\alpha\beta$ lineage-committed thymocytes, whereas in most $\gamma\delta$ lineage T cells and thymocytes the
104 *TRB* locus was still in germline configuration [49–51]. Moreover, rearrangement of both *TRG*
105 alleles was detected in a large proportion of $\gamma\delta$ T cells [51], which indicates that V(D)J
106 recombination is initiated and potentially also completed much earlier at the *TRG* compared
107 to the *TRB* locus. This implies sequential albeit overlapping rearrangement windows in the
108 order *TRD-TRG-TRB* in human thymocytes.

109 The human *TRG* locus comprises seven functional *TRGV* elements and two *TRGJ* arrays
110 which are each associated with one *TRGC* element (Figure 3). During fetal development cells
111 predominantly rearrange the central *TRGV* elements, which are recombined with the central J
112 array and paired with *TRGCI*, whereas postnatal thymocytes mainly use distal *TRGV* and

113 *TRGJ* segments in combination with *TRGC2* [52,53]. The *TRD* locus contains eight *TRDV*
114 segments, of which *TRDV4-8* also have *TRA* designation due to the nested localisation of
115 *TRD* within the *TRA* locus. In addition, three *TRDD*, four *TRDJ* and a single *TRDC* segment
116 can be utilised during V(D)J recombination. The downstream *TRDV* and *TRDJ* elements are
117 predominantly rearranged in fetal thymocytes and a shift towards more upstream elements
118 occurs later in life [52,54,55] (Figure 3). This differential use of V-segments is reflected in
119 the distinct $\gamma\delta$ T cell types that arise during certain developmental windows, for example,
120 $V\gamma9+V\delta2+$ cells represent the main subset generated in early gestation whereas $V\delta1+$ cells
121 dominate after birth, as discussed below.

122 In addition, repertoires of embryonic, fetal and postnatal $\gamma\delta$ thymocytes differ in their
123 incorporation of nucleotides during V(D)J recombination. This is a consequence of delayed
124 induction of terminal deoxynucleotidyl transferase (TdT, encoded by the *DNTT* gene) in fetal
125 thymocytes at around 20 weeks post conception (wpc) [56], resulting in highly invariant
126 germline-encoded CDR3 sequences in $\gamma\delta$ T cells generated during early development [54]. A
127 likely regulator of TdT expression is the RNA-binding protein LIN28B, which is highly
128 expressed in fetal but not postnatal $\gamma\delta$ T cells and causes inhibition of TdT, a reduction of N
129 additions and more invariant CDR3 sequences upon overexpression in cord blood-derived
130 HSPCs [54]. Surprisingly, increased LIN28B levels in peri-/postnatal HSPCs also result in
131 preferential usage of *TRDV2* over *TRDV1*, which mimics fetal thymocyte development and
132 indicates a direct impact of LIN28B on the regulation of V(D)J recombination [54].

133 Moreover, it has been suggested that in absence of TdT, short homology repeats at certain
134 V/D/J segments can drive recombination and thereby promote the generation of specific
135 germline-encoded sequences in fetal $\gamma\delta$ thymocytes [54,57]. These findings imply that certain
136 aspects of V(D)J recombination differ by gestational age due to intrinsic properties of the
137 progenitor cells and this has a phenotypic and functional impact on the generated $\gamma\delta$ T cells.

138

139 **2.2.1 Allelic exclusion of the γ - and δ -chain**

140 Allelic exclusion describes the process of achieving monoallelic expression of a gene, which,
141 in the T cell context, critically determines if a cell can express one or multiple different TCRs
142 on the cell surface. Studies investigating the frequencies of in-frame *TRG* and *TRD*
143 rearrangements in $\gamma\delta$ T cells from thymus and peripheral blood reported a large proportion of
144 cells with functional rearrangements at both *TRG* alleles [50,53,58,59]. This suggests allelic
145 inclusion for this locus and therefore the possibility that two different γ -chains can be
146 expressed on the same cell, which has indeed been demonstrated in $\gamma\delta$ T cell lines [60]. In
147 contrast, although biallelic rearrangements have been observed at the *TRD* locus, these are
148 less frequent and overwhelmingly appear to represent incomplete or out-of-frame
149 rearrangements [50,58,59], indicating allelic exclusion for the δ -chain. Of note, productive
150 rearrangements at both the *TRD* and the *TRG* locus may not guarantee the successful
151 assembly of a functional $\gamma\delta$ TCR due to incompatibility between certain γ - and δ -subunits.
152 This has only been confirmed for murine but not human $\gamma\delta$ T cells [61,62], but such a pairing
153 restriction might partially account for the described biallelic in-frame rearrangements. That
154 being said, a small proportion of cells with surface expression of multiple different δ -chains
155 has been observed in cell lines [63], which suggests that allelic exclusion is incomplete and
156 may simply vary in stringency between different loci. Curiously, analyses in mice suggest an

157 inverse allelic exclusion pattern, with *TRG* but not *TRD* being allelically excluded [64–66].
158 This bears a resemblance to the general understanding that for human $\gamma\delta$ T subsets the δ -
159 chain seems to be the distinguishing feature, whereas murine $\gamma\delta$ T subtypes can be grouped
160 by their γ -chain, and might therefore imply a stricter exclusion control for the phenotype-
161 determining TCR subunit.

162

163 **2.2.2 Regulation of *TRD/TRG* rearrangement**

164 The factors and molecular processes that initiate and control V(D)J recombination at the *TRD*
165 and *TRG* loci in human are still largely unknown, but some hints might be found in mouse
166 studies. For instance, the role of IL7R signalling in the regulation of *Trg* rearrangement in
167 murine thymocytes has been well documented. IL7R-deficient mice exhibit defects in $\gamma\delta$ T
168 cell development, which seem to be at least partially inflicted by impaired recombination at
169 the *Trg* locus [67–71] since a rearranged *Trg* transgene is able to rescue the phenotype [72].
170 IL7 signalling has been linked with increased histone acetylation, chromatin accessibility,
171 transcription and rearrangement at the *Trg* locus [70,72–76], which has been attributed to
172 IL7-induced recruitment of STAT5 to the *Trg* enhancer E γ [73,77] (Figure 2B). Evidence for
173 IL7-mediated *TRG* rearrangement in human thymocytes is more sparse, but it has indeed
174 been demonstrated that IL7R signalling can activate STAT5 [44], which binds to conserved
175 STAT consensus motifs at *TRG* regulatory regions and drives germline transcription at the
176 locus [78]. Moreover, $\gamma\delta$ T cells from patients with instability-inducing mutations in *IL7R*
177 exhibit an unusually restricted *TRG* repertoire and reduced activation of STAT5 in response
178 to IL7 stimulation [79], which further supports a role of IL7 in *TRG* rearrangement during
179 human $\gamma\delta$ T cell development. Surprisingly, while knock-out experiments in mice targeting
180 various IL7 pathway components, such as *Il7ra*, *Jak3* and *Il2rg*, resulted in disrupted $\gamma\delta$ T
181 cell development regardless of age [68,80,81], STAT5 deficiency only perturbed *Trg*
182 rearrangement and $\gamma\delta$ T cell differentiation in fetal but not adult mice [76]. This indicates that
183 while IL7R signalling is generally required for *Trg* rearrangement in mouse thymocytes, the
184 downstream mediators may vary throughout development. In contrast to the *Trg* locus, IL7R
185 deficiency in mice does not seem to disrupt the generation of a functional δ -chain [67,68],
186 although a recent study demonstrated IL7/STAT5-dependent induction of germline
187 transcription at the E δ enhancer [82], which suggests a previously overlooked role of IL7 at
188 this locus. In human, E δ activity was shown to be induced by IL7 treatment of Jurkat cells
189 [82], suggesting a possible involvement of IL7R signalling activity in *TRD* rearrangement.
190 Furthermore, a xenograft study with HSPCs derived from IL7R-deficient severe combined
191 immunodeficiency (SCID) patients reported that cells were able to mature until the ETP stage
192 but did not initiate *TRD* rearrangements [83]. This could indicate a potential role for IL7 in
193 the recombination of the human *TRD* locus, but the absence of *TRD* rearrangements could
194 also merely be a consequence of the early developmental block and general defects in
195 thymocyte development.

196 E proteins, in particular HEB and E2A, have been found to play a crucial role in the
197 regulation of V(D)J recombination at the *TRG* and *TRD* locus. In mice, E2A has been
198 implicated in the stage-specific control of *Trg* rearrangement by selectively promoting or
199 repressing the recombination of certain *Trgv* elements during fetal or adult $\gamma\delta$ T cell
200 development [84,85]. Similarly, two independent transfection studies demonstrated that E2A

201 and HEB can induce V(D)J recombination at the human *TRG* and *TRD* loci in non-lymphoid
202 cells [86,87]. The detected rearrangements were limited to certain segments, which seems to
203 confirm that E protein-mediated control of recombination is targeted to specific *TRG/D*
204 regions. Moreover, based on elevated levels of germline transcription upon E protein
205 transfection, it was hypothesised that E2A and HEB regulate accessibility at recombination
206 signal sequence (RSS) sites [87], which supports a local rather than global role of E proteins
207 in the regulation of TCR locus rearrangement. Recent transcription factor footprinting
208 analyses from our lab have predicted a large number of E2A binding sites throughout the
209 *TRD* and *TRG* loci, which were associated with open chromatin and permissive histone marks
210 in CD34+ thymocytes and could thus indicate involvement of the E protein in controlling
211 chromatin state and germline transcription at the loci in developing thymocytes [88] (Figure
212 2B). Furthermore, using single cell data, we found that *E2A* RNA levels were positively
213 correlated with those of *TRGC2*, which points towards a role of E2A in *TRG* germline
214 transcription or expression of the rearranged γ -chain [88]. Notably, the rearrangements
215 reported from transfection experiments appear to be comparable to those that are normally
216 observed in thymocytes prior to T lineage commitment and only involve D-D and V-D but
217 not D-J recombinations, which implies that E proteins might participate in the initiation but
218 not necessarily progression and completion of *TRG/TRD* rearrangement [86,87]. E proteins
219 have also been shown to induce *RAG* expression [89,90], which constitutes an additional
220 mechanism by which this subset of transcription factors can control V(D)J recombination
221 (Figure 2B).

222 Notch signalling has also been implicated in the control of TCR rearrangement in human
223 thymocytes, as cord blood-derived HSPCs cultured in the presence of the Notch ligand DLL4
224 showed recombination of certain *TRGV* elements [37]. Mechanistically, it has been reported
225 that Notch signalling can induce the expression of *IL7R* under certain conditions [82,91],
226 which consequently promotes TCR rearrangement as described above. In addition, Notch
227 upregulates the transcription factors MYB and RUNX1 [91], which both bind at regulatory
228 elements at the *TRG* and *TRD* loci [77,92–96] (Figure 2B). RUNX factors have been
229 suggested to act as pioneering factors that are required to promote chromatin accessibility and
230 thus permit recruitment of MYB, GATA3 and STAT5 to the TCR loci [77,95], which
231 subsequently leads to activation of the E δ and E γ enhancers and germline transcription
232 [91,92,97–99]. Of note, while RUNX1 appears to be responsible for this pioneering activity
233 in immature thymocytes, its paralog RUNX3 most likely fulfils this role in mature $\gamma\delta$ T cells
234 [100,101]. Curiously, in addition to this positive impact of Notch signalling on *TRD* and *TRG*
235 rearrangement, it also seems to exhibit some degree of negative control over the process:
236 Notch activity can restrain E protein function via induction of the inhibiting factor ID3 [102–
237 104] and is further able to initiate degradation of E2A via ERK signalling-mediated
238 phosphorylation [102], which might consequently interfere with TCR locus accessibility and
239 V(D)J recombination. In addition, reduction of Notch signalling leads to increased *RAG*
240 expression [101,105], which implies a potential Notch-induced suppression or termination of
241 TCR rearrangement via downregulation of *RAG* (Figure 2C).

242 Importantly, the discussed pathways and transcription factors appear to be closely connected,
243 as shown by Notch-mediated induction of *IL7R* expression and RUNX-dependent STAT5
244 recruitment, as well as the negative control of E protein activity by Notch signalling. This

245 demonstrates the intricacies of the molecular processes governing the rearrangement of *TRG*
246 and *TRD* loci and illustrates the pitfalls of studying either of the pathways in isolation.
247 Moreover, the previously described roles of Notch and IL7 in thymocyte survival and T
248 lineage commitment complicate their investigation at a later developmental stage and make it
249 difficult to distinguish TCR rearrangement-dependent and -independent effects on maturation
250 and differentiation of $\gamma\delta$ T cells progenitors. Hence, further investigation is needed to
251 establish which factors drive recombination of the *TRG* and *TRD* loci and how changes in V,
252 D and J element usage are regulated through human ontogeny.
253 Rearrangement of the *TRD/TRG* loci is suspended upon commitment to the $\gamma\delta$ lineage (Figure
254 2C). This is triggered by TCR signalling, which blocks E protein activity by inducing the
255 expression of Id3 [106]. In addition, TCR signalling was shown to downregulate Notch
256 targets, including *MYB* and *RUNXI*, and thereby inhibits E δ activity [91]. Lastly, the
257 upregulation of c-Jun in response to TCR activity seems to suppress *IL7R* expression [107],
258 which is expected to interfere with its control of TCR rearrangement. Hence, the assembly of
259 a functional $\gamma\delta$ TCR triggers a negative feedback loop that prevents further rearrangement of
260 the TCR loci.

261

262 **3 Commitment to the $\gamma\delta$ lineage**

263

264 The exact point at which bipotent progenitors fully commit to the $\alpha\beta$ or the $\gamma\delta$ lineage has
265 been difficult to determine and may in fact not be associated with a certain developmental
266 stage (see section 3.2). Furthermore, the definition of these two lineages has been somewhat
267 ambiguous. Thus far, no unique surface marker for $\gamma\delta$ T cells other than the $\gamma\delta$ TCR itself has
268 been identified, which has therefore been used as indicator of $\gamma\delta$ fate in most studies. On the
269 other hand, since no TCR is expressed on the surface of early $\alpha\beta$ committed cells, the DP
270 stage has often been described as an $\alpha\beta$ lineage-specific characteristic. Especially in
271 experimental settings these markers often do not hold up, for instance, premature expression
272 of a transgenic $\alpha\beta$ TCR leads to TCR $\alpha\beta$ ⁺ cells with a clear $\gamma\delta$ lineage phenotype, including
273 effector behaviour and lack of CD4/CD8 expression [108–110]. Similarly, TCR $\gamma\delta$ ⁺ cells that
274 develop in the absence of DP thymocytes do not adopt a $\gamma\delta$ lineage gene expression
275 programme [111] and TCR $\gamma\delta$ -transgenic RAG-deficient mice develop TCR $\gamma\delta$ ⁺ DP
276 thymocytes [112,113]. Even in the physiological context $\gamma\delta$ TCR expression and DP
277 phenotype do not seem to be mutually exclusive, since human $\gamma\delta$ lineage cells appear to be
278 able to differentiate via a transient DP stage [114,115]. Establishment of unambiguous
279 lineage gene expression profiles and identification of additional lineage-specific surface
280 markers are required to resolve this issue, but in the meantime, caution is required in the
281 interpretation of studies that rely on DP vs. TCR $\gamma\delta$ ⁺ phenotype as a means of lineage
282 distinction.

283

284 **3.1 Molecular mechanisms involved in the fate decision**

285 **3.1.1 TCR signalling and its impact on lineage commitment**

286 How the TCR plays into the $\alpha\beta$ vs. $\gamma\delta$ fate decision has long been a matter of debate. Initially,
287 two scenarios were proposed; an instructive model, according to which cell fate is informed
288 by the type of assembled TCR, and a stochastic model, whereby lineage fate is pre-

289 programmed and only cells with a matching TCR survive. In support of a stochastic principle,
290 some indication of hard-wired $\gamma\delta$ cell fate in mice has been presented. For instance, DN
291 thymocytes with high levels of SOX13 or IL7R were found to exhibit a higher potential to
292 develop along the $\gamma\delta$ lineage [116–118], although concerns have been voiced that some of
293 these results might be biased by the positive impact of IL7 on *Trg* rearrangement (see section
294 2.2.2). On the other hand, an instructive fate decision model is currently well supported by
295 several lines of evidence. Curiously, it was shown that the lineage choice is not informed
296 through a qualitative difference in the signals transduced by pre-TCR vs. $\gamma\delta$ TCR but rather
297 through differential signal strength. Initial experiments revealed higher Ca²⁺ mobilisation,
298 mitogen-activated protein kinase (MAPK) signalling, and stronger induction of the
299 transcription factor EGR in $\gamma\delta$ compared to $\alpha\beta$ lineage cells [113,119,120], suggesting greater
300 signalling activity through the $\gamma\delta$ TCR than through the pre-TCR. Two landmark studies from
301 the labs of David Wiest and Paul Love then demonstrated that although under normal
302 conditions the $\gamma\delta$ TCR conveys strong signals and this quantitative signal difference
303 constitutes the decisive element, it does not seem to be categorically linked with the TCR
304 type. Instead, dampening of $\gamma\delta$ TCR signalling strength by manipulation of ITAMs or Lck
305 deficiency was sufficient to divert cells away from $\gamma\delta$ fate and towards the $\alpha\beta$ lineage,
306 whereas elevated signal strength achieved through ligand engagement or CD5 deficiency
307 resulted in a reduction of the DP thymocyte fraction in favour of $\gamma\delta$ development [113,120].
308 The signal strength hypothesis was further corroborated by lineage tracing experiments in
309 individual cells, which verified that DN thymocytes can be diverted to the $\gamma\delta$ lineage through
310 induction of strong TCR signals, even if the cells have already reached the β -selection stage
311 [121]. Moreover, cells co-expressing pre-TCR and $\gamma\delta$ TCR develop along the $\gamma\delta$ lineage and
312 adopt a $\gamma\delta$ gene expression profile, which implies that strong signalling activity by the $\gamma\delta$
313 TCR dominates over weak pre-TCR signals [122]. Additional studies attempted to elucidate
314 the means by which the two types of receptors achieve different signal intensities and found
315 discrepancies in the use of downstream pathway components, membrane localisation and
316 cytoplasmic domain structure between pre-TCR and $\gamma\delta$ TCR [123–127]. Moreover, it has
317 been suggested that a higher absolute abundance of $\gamma\delta$ TCR on the cell surface could be
318 responsible for the stronger signalling intensity [20,128], which is supported by the finding
319 that reduction of $\gamma\delta$ TCR expression levels in transgenic mice promotes the development of
320 TCR $\gamma\delta$ ⁺ DP thymocytes [120].
321 For both $\gamma\delta$ TCR and pre-TCR the main signalling cascade that is triggered downstream is the
322 MAPK pathway, which stimulates the phosphorylation and activation of ERK. This in turn
323 mediates the upregulation of EGR transcription factors, which induce expression of their
324 target *Id3* [106,129,130]. Importantly, the levels of ERK phosphorylation and EGR/ID3
325 induction are proportional to the TCR activity and therefore higher in TCR $\gamma\delta$ ⁺ cells
326 compared to pre-TCR⁺ cells [106,113,119,120,129,130]. Further research by Lee et al. has
327 provided additional insight into how the differences in ERK activation might be translated
328 into distinct gene expression programmes in $\alpha\beta$ and $\gamma\delta$ lineage cells. The authors observed
329 that in cells adopting $\gamma\delta$ fate, ERK phosphorylation was not just stronger but also maintained
330 for a longer period of time after removal of the TCR stimulus [131]. This prolonged ERK
331 activity enabled the interaction and posttranslational stabilization of the transcriptional target
332 EGR1 through the ERK DEF binding pocket. Such non-canonical ERK signalling has

333 previously been described for other immediate early genes [132,133] and implies that certain
334 DEF domain-containing proteins might be stabilised only upon $\gamma\delta$ TCR signalling, whereas
335 pre-TCR-mediated ERK activation may be too transient to mediate stabilisation of its
336 transcriptional targets. This could represent a way in which a differential gene expression
337 programme can be established in response to pre-TCR vs. $\gamma\delta$ TCR signalling [133].
338 Importantly, the role of TCR signalling in the fate decision process has primarily been
339 studied in the mouse context and therefore the abovementioned mechanisms have yet to be
340 substantiated in human thymocytes. Recent work from our lab revealed that in the human
341 thymus commitment to the $\gamma\delta$ lineage is associated with extensive changes in the chromatin
342 landscape and that the differentially accessible regions in TCR $\gamma\delta$ + thymocytes are enriched
343 for motifs of AP-1 family transcription factors [134], which represent known downstream
344 targets of TCR signalling [135]. AP-1 activity has indeed been shown to play a crucial role in
345 chromatin opening during TCR-induced T cell activation [136], which substantiates the idea
346 that changes in chromatin accessibility in cells differentiating along the $\gamma\delta$ lineage are
347 mediated by TCR signalling. Importantly, no such alterations in the chromatin landscape
348 were observed in β -selected thymocytes that are predicted to have received a weak pre-TCR
349 signal. TCR stimulation of such immature $\alpha\beta$ lineage ISP thymocytes prevented transition to
350 the DP stage and instead resulted in the development of CD4-CD8+CD73+ thymocytes,
351 which resemble immature $\gamma\delta$ T cells. Moreover, the TCR-stimulated cells displayed wide-
352 spread chromatin opening, similar to the previously observed changes in $\gamma\delta$ lineage cells
353 [134]. Finally, thymocytes committing to the $\gamma\delta$ but not the $\alpha\beta$ lineage were found to
354 upregulate *EGR* transcription factors as well as *ID3* [134], which constitute downstream
355 targets of TCR signalling as discussed above. While more research is needed to definitively
356 link TCR signalling intensity and $\alpha\beta$ vs. $\gamma\delta$ cell fate in human thymocytes, these observations
357 strongly suggest that the signal strength-based instructional model holds true in the context of
358 human T cell development.

359

360 **3.1.2 The role of Notch signalling in the lineage decision**

361 Notch signalling in the context of T cell development has been studied extensively; however,
362 several discrepancies between mouse and human have made the interpretation of
363 experimental results rather complicated (Table 1). Specifically, Notch signalling in mouse
364 thymocytes favours development of the $\alpha\beta$ over the $\gamma\delta$ lineage, whereas several lines of
365 evidence suggest the opposite in human T cell development. Overexpression of ICN1 or
366 ICN3 – the active intracellular domains of Notch1 and Notch3, respectively – in human
367 thymocytes was shown to skew T cell development towards the $\gamma\delta$ lineage in a proliferation-
368 independent manner [33,41,137]. The ICN1-mediated skewing was more prominent when
369 CD34+ thymocytes were used as starting population, whereas only a mild effect was
370 observed with ISP thymocytes and cells past the β -selection point could not be reverted to $\gamma\delta$
371 fate via ICN1 overexpression [41], which is in line with the gradual loss of $\gamma\delta$ potential
372 throughout development. These findings were further corroborated in two studies that
373 employed γ -secretase inhibitor (GSI) to block cleavage-mediated activation of Notch1, which
374 resulted in impaired $\gamma\delta$ lineage development from CD34+ precursors in the OP9-DLL co-
375 culture system and in human/mouse Fetal Thymic Organ Cultures (FTOCs) [41,101]. The
376 studies disagreed on the requirement of Notch signalling for $\alpha\beta$ lineage development, with

377 increased frequencies of DP and TCR $\alpha\beta$ + cells in the OP9 system but reduced DP numbers in
378 the FTOCs. This discrepancy can most likely be explained by differing GSI concentrations
379 and therefore different residual levels of Notch activity, given that subsequent analyses in
380 *Dll4^{lox/lox}/Jag2^{lox/lox}* FTOCs demonstrated a dose-dependent reduction of $\gamma\delta$ lineage cells but
381 normal $\alpha\beta$ lineage development as long as at least one *Dll4* or *Jag2* allele was intact [138].
382 This substantiates a higher Notch dependency of differentiating $\gamma\delta$ T cells compared to $\alpha\beta$
383 lineage cells during human thymocyte development. In fact, high levels of Notch activity
384 seem to impede $\alpha\beta$ T cell development as observed by the beneficial effects of low doses of
385 GSI and the negative impact of ICN1 overexpression on the $\alpha\beta$ lineage [39,41,101].
386 When assessed in isolation using the OP9 co-culture system, JAG2 appears to be the Notch
387 ligand that best supports $\gamma\delta$ T cell development from CD34+ thymocyte precursors [33]. This
388 has been attributed to its ability to interact with both Notch1 and Notch3 on immature
389 thymocytes, which leads to strong Notch signalling activity [33]. DLL1 and DLL4 can also
390 support $\gamma\delta$ T cell development, yet in OP9 co-cultures they also promote the differentiation of
391 a higher proportion of $\alpha\beta$ lineage cells [33,101,137,139]. These assays demonstrate that either
392 of the three ligands is sufficient to permit $\gamma\delta$ T cell development, but due to their redundancy,
393 neither of them is absolutely required for this process. This is further illustrated by *Jag2^{-/-}*
394 FTOC experiments, in which $\gamma\delta$ T cell development is reduced but not completely abrogated
395 [33]. Similarly, $\gamma\delta$ lineage cells can still develop to a certain extent in *Dll4^{-/-}/Jag2^{w^t-}* or
396 *Dll4^{w^t-}/Jag2^{-/-}* FTOCs and only *Dll4/Jag2* double-deficient thymic lobes entirely disrupt $\gamma\delta$ T
397 cell differentiation. In contrast, JAG1 is not able to support efficient differentiation of $\gamma\delta$
398 lineage cells due to its weak interactions with Notch1 and Notch3 [33] and *Jag1*-deficient
399 FTOCs exhibit normal $\gamma\delta$ T cell development [138]. Importantly, the expression of the
400 different Notch ligands is not homogenous throughout the thymus lobes, with DLL4 mostly
401 found in cortical TECs, whereas JAG2 is expressed in the cortex and medulla [139,140]. It
402 has been hypothesised that this results in the generation of distinct niches, which permit the
403 regulation of specific Notch-dependent developmental decisions such as T lineage
404 commitment or $\alpha\beta$ vs. $\gamma\delta$ cell fate specification [140]. Based on this, 2D or 3D cell culture
405 systems with homogenous ligand distribution may exhibit some technical bias and not reflect
406 the thymic microenvironment in full accuracy. Similarly, the DLL4 and JAG2 expression
407 levels and localisation differ between human and mouse thymus [140] (Table 1), which might
408 affect timing and intensity of Notch signalling in the FTOC system. These limitations need to
409 be considered during the interpretation of experimental findings.

410 While the Notch targets that mediate T lineage commitment are well known [105], the
411 molecular mechanism through which strong Notch signalling favours $\gamma\delta$ lineage fate remains
412 largely unclear. This gap may be due to certain obstacles in the analysis and interpretation of
413 Notch activity, for instance, divergent Notch1 and Notch3 expression windows (Figure 1), a
414 lack of information about target gene redundancy between these two receptors [33] and an
415 apparent difference in dose-sensitivity for certain Notch targets [101]. Recently, it was shown
416 that Notch signalling counteracts the expression of BCL11B, a transcription factor that is
417 essential for $\alpha\beta$ lineage development but less crucial for the $\gamma\delta$ lineage [138]. Moreover, as
418 previously mentioned, IL7R appears to be upregulated in response to Notch signalling
419 [38,82] and might support the development of $\gamma\delta$ T cells through its involvement in
420 *TRG/TRD* rearrangement. The normal use of *TRGV* and *TRDV* elements in $\gamma\delta$ T cells derived

421 from *Jag2*^{-/-} FTOCs argues against this idea [33], but an in-depth analysis of the repertoire
422 would be required to draw a definitive conclusion. Moreover, TCR $\gamma\delta$ +CD73- thymocytes that
423 have not yet fully committed to $\gamma\delta$ fate are still dependent on Notch signalling for their
424 maturation, which indicates a role of Notch signalling in $\gamma\delta$ lineage development beyond
425 TCR rearrangement [138].

426

427 **3.1.3 IL7R signalling during $\gamma\delta$ commitment**

428 Similar to Notch signalling, studies in different species have indicated differing requirements
429 for IL7 signalling in $\gamma\delta$ T cell development. Mice deficient in IL7 pathway components, such
430 as IL7R, JAK3, or STAT5, display significant impairments in the $\gamma\delta$ lineage while $\alpha\beta$ T cells
431 are only moderately affected [73,81,141,142]. Likewise, in medaka, where $\gamma\delta$ T cell
432 development in the thymus is spatially separated from $\alpha\beta$ development, IL7 is predominantly
433 expressed by cells in the $\gamma\delta$ niche and IL7 overexpression promotes $\gamma\delta$ T cell development
434 [143]. In contrast, IL7-mutant zebrafish show no substantial disruption of $\alpha\beta$ and $\gamma\delta$ lineage
435 differentiation [144]. Contradicting findings have been reported in the context of human $\gamma\delta$ T
436 cell development: Pallard and colleagues showed that when CD34+ thymocytes cultured in
437 FTOCs were treated with IL7R inhibitory antibodies, $\alpha\beta$ lineage development was
438 completely disrupted but $\gamma\delta$ T cells could still differentiate, albeit at reduced frequencies [44].
439 In addition, a dominant negative form of STAT5B resulted in impaired $\alpha\beta$ T cell
440 development but $\gamma\delta$ lineage expansion in FTOCs [44], suggesting a much stronger
441 dependence of $\alpha\beta$ lineage cells on IL7R signalling activity. On the other hand, increasing
442 concentrations of IL7 in CD34+ OP9-DLL1 co-cultures promoted both $\alpha\beta$ and $\gamma\delta$ lineage
443 development but the beneficial impact was more prominent in the $\gamma\delta$ lineage [101]. Analysis
444 of prenatal and paediatric thymocyte samples also revealed a $\gamma\delta$ lineage-specific upregulation
445 of IL7R signalling components, such as *IL7R*, *STAT5A*, *STAT5B* and *JAK3* [134,145], and
446 chromatin opening at the *IL7R* locus [134], which implies a beneficial effect of IL7R
447 signalling on human $\gamma\delta$ T cell development. Insights from patients with IL7R mutations into
448 the role of IL7 in $\gamma\delta$ lineage differentiation are difficult to obtain due to the role of IL7 in T
449 lineage commitment and the resulting early arrest of thymocyte development. However,
450 STAT5B gain-of-function mutations seem to be very common in $\gamma\delta$ T cell lymphoma
451 [146,147], which indicates that this downstream mediator of IL7R signalling might provide a
452 growth advantage in $\gamma\delta$ T cells. Due to these limited and partially conflicting data, definitive
453 conclusions about the involvement of IL7R signalling in human $\gamma\delta$ lineage commitment
454 cannot be drawn. Moreover, the impact of the IL7R pathway on TCR rearrangement is
455 difficult to separate from any additional roles of IL7 in the fate decision and further research
456 is therefore needed to address this question.

457

458 **3.1.4 Transcriptional regulation of $\gamma\delta$ lineage commitment**

459 Despite the advances in high-throughput sequencing approaches, the identification of
460 transcription factors that are required and sufficient to establish $\gamma\delta$ fate has been surprisingly
461 difficult. A transcriptional signature of mouse $\gamma\delta$ thymocytes, including *ICER*, *Sox13*, *Runx3*,
462 *Id3* and several NR4A nuclear receptor factors, was described by the Hayday lab [111].
463 However, most of these factors were already detectable in DN thymocytes and were later
464 selectively downregulated in the $\alpha\beta$ but not in the $\gamma\delta$ lineage. Moreover, many were found to

465 be expressed in other unconventional T cell types, such as TCR $\alpha\beta$ + CD8 $\alpha\alpha$ cells, and are
466 therefore not specific to the $\gamma\delta$ lineage [111,148].

467 The prime candidates as $\gamma\delta$ -promoting regulators in the lineage fate decision are perhaps
468 EGR1-3 and ID3, which are upregulated in response to TCR signalling. As discussed above,
469 their induction levels are proportional to the intensity of TCR activity and therefore
470 especially high in $\gamma\delta$ thymocytes, yet pre-TCR signalling is also able to induce *Egr/Id3*
471 expression in $\alpha\beta$ lineage cells [106,113,119,120,129,130]. Analyses from our lab showed that
472 these findings from mouse studies are mirrored in human thymocytes, with immature
473 TCR $\gamma\delta$ +CD1+ thymocytes displaying much higher levels of *EGR1-3* and *ID3* compared to β -
474 selected ISP thymocytes [134]. In addition, using single cell data we discovered a strong but
475 highly transient upregulation of *ID3* in cells undergoing β -selection [88], which further
476 confirms that *ID3* is expressed in the course of commitment to both $\alpha\beta$ and $\gamma\delta$ lineage.

477 Ectopic expression of *ID3* in CD34+ fetal liver cells or CD34+CD1- HSPCs in the FTOC
478 system has been shown to prevent T lineage commitment and interferes with the induction of
479 *TRD* rearrangements [149,150], which can probably be attributed to *ID3*-mediated inhibition
480 of E protein activity as well as the downregulation of *RAG1/2* [149] (Figure 2C). In contrast,
481 overexpression of *ID3* in cells that have already committed to the T lineage and initiated TCR
482 rearrangements only impairs the development of $\alpha\beta$ lineage cells, whereas $\gamma\delta$ T cells
483 differentiate normally [149]. Importantly, the elevated *ID3* levels do not seem to divert cells
484 to the $\gamma\delta$ fate as indicated by stable frequencies of TCR $\gamma\delta$ + thymocytes. This resembles
485 findings in mice, where *ID3* overexpression is unable to promote increased $\gamma\delta$ lineage
486 commitment [113] and implies that *ID3* is insufficient for induction of $\gamma\delta$ fate.

487 Mechanistically, in mouse thymocytes *ID3* interferes with the E protein-induced initiation of
488 gene expression programmes that are required for $\gamma\delta$ effector differentiation [151]; however,
489 this specification does not seem to apply in the human thymus (see section 4.1) and therefore
490 the mechanisms through which *ID3* contributes to $\gamma\delta$ T cell development in the human
491 context remain unclear.

492 Another transcriptional regulator with potential involvement in $\gamma\delta$ T cell differentiation is
493 SOX13. Initial mouse experiments showed impaired $\gamma\delta$ but not $\alpha\beta$ lineage development in
494 *Sox13*-deficient mice and increased TCR $\gamma\delta$ + but reduced DP thymocyte frequencies upon
495 SOX13 overexpression [117]. Moreover, SOX13 expression in DN thymocytes was found to
496 be heterogeneous and high SOX13 levels were predictive of increased $\gamma\delta$ lineage potential
497 [116]. However, subsequent studies demonstrated that SOX13 is not expressed in all $\gamma\delta$ T
498 cells [152] but appears to be required solely for differentiation of the $\gamma\delta$ T17 subtype via the
499 induction of the $\gamma\delta$ T17 transcriptional programme [153,154]. In human thymocytes, *SOX13* is
500 also upregulated in $\gamma\delta$ lineage cells, whereas in the $\alpha\beta$ lineage the locus exhibits increased
501 levels of repressive H3K27me3 marks [134,155]. Since there is no human equivalent of the
502 murine $\gamma\delta$ T17 subset, it still needs to be established if and how SOX13 could play a role in
503 human $\gamma\delta$ T cell development.

504 RUNX3 is a transcription factor primarily known for its role in establishing CD8+ cytotoxic
505 T cells through repression of alternative T helper fate [156] but it is also upregulated during
506 $\gamma\delta$ lineage commitment and downregulated in cells undergoing β -selection [101,134].
507 Interestingly, analysis of chromatin accessibility and histone modifications at the *RUNX3*
508 locus throughout thymocyte differentiation revealed high levels of H3K27ac at the

509 transcription start site of a short *RUNX3* isoform in TCR $\gamma\delta$ ⁺ but not CD8⁺ SP thymocytes
510 [134], which suggests that the two cell types might use different isoforms of *RUNX3* or at
511 least engage in different mechanisms of transcriptional regulation. As described earlier,
512 *RUNX3* may act as a pioneering factor at the *TRG/TRD* loci to facilitate $\gamma\delta$ TCR expression
513 in mature $\gamma\delta$ T cells [100], but further functions in this context remain to be elucidated.
514 Several other transcription factors identified in mouse $\gamma\delta$ T cells also seem to be selectively
515 upregulated in human $\gamma\delta$ lineage thymocytes but repressed in the $\alpha\beta$ lineage, including
516 *NR4A1-3*, *ETV5*, *KLF2*, *RELB*, *HES1* and *ZBTB16* [111,134,157,158]. *TBX21* (encoding T-
517 bet), which has previously been implicated in murine $\gamma\delta$ T cell development and function
518 [159,160], was expressed at elevated levels in human TCR $\gamma\delta$ ⁺ thymocytes and shut down
519 during β -selection via promoter histone methylation [134]. *TBX21* motifs were found to be
520 enriched in accessible chromatin regions in $\gamma\delta$ T cells, suggesting high activity of the
521 transcription factor in this lineage [134]. On the other hand, a subset of transcriptional
522 regulators with known involvement in mouse $\gamma\delta$ T cell differentiation seems to be expressed
523 at low levels in human TCR $\gamma\delta$ ⁺ thymocytes [111,134,153], which highlights that not all $\gamma\delta$ -
524 biased transcription factors are conserved between species. Importantly, in mouse
525 thymocytes, many of the listed genes have been linked with the adoption of a specific $\gamma\delta$ T
526 cell effector fate in the thymus, which does not seem to apply in the human context and
527 therefore creates difficulties in translating molecular functions between species.
528 Epigenetic regulation of $\gamma\delta$ T cell development and the $\alpha\beta$ vs. $\gamma\delta$ fate decision has not been
529 studied in much detail. Our lab recently described widespread chromatin remodelling, which
530 occurred specifically in $\gamma\delta$ lineage committed thymocytes, whereas $\alpha\beta$ lineage cells retained a
531 stable chromatin landscape throughout β -selection [134]. This was despite extensive
532 transcriptional changes in both lineages, which implies that gene expression is regulated
533 through different mechanisms in $\alpha\beta$ vs. $\gamma\delta$ committed cells. Differentially accessible regions
534 in TCR $\gamma\delta$ ⁺ cells were mostly located in intronic and intergenic regions, suggesting that
535 differential gene expression is predominantly controlled by changes at distal enhancers [134].
536 Given the complexities associated with enhancer annotation, this may explain difficulties in
537 the establishment of $\gamma\delta$ -specific gene regulatory networks. In contrast, $\alpha\beta$ lineage thymocytes
538 displayed upregulation of components of the Polycomb Repressive Complex 2 (PRC2), such
539 as *SUZ12* and *EZH2*, and consistent with this, a global increase in H3K27me3 levels was
540 detected [134]. The repressive histone mark was found in $\alpha\beta$ thymocytes at the regulatory
541 regions of many $\gamma\delta$ -biased genes, including *SOX13*, *ZBTB16*, *TBX21*, *RUNX3*, *EGR1* and
542 *NT5E* (encoding CD73), which implies that transcription of these is shut down in the $\alpha\beta$
543 lineage via PRC2 complex activity. TCR $\gamma\delta$ ⁺ cells on the other hand exhibited upregulation of
544 the H3K27me3 erasers *KDM6A* and *KDM6B* and consequently a very limited increase in
545 H3K27me3 [134]. To our knowledge, no studies have been published addressing DNA
546 methylation in connection with the $\alpha\beta$ vs. $\gamma\delta$ fate decision in human thymocytes. However,
547 we found that commitment to the $\gamma\delta$ lineage and maturation of $\gamma\delta$ cells is associated with
548 upregulation of *TET2* and *TET3* and consequently with large-scale CpG demethylation. In
549 contrast, $\alpha\beta$ lineage cells displayed few changes in DNA methylation until the DP-to-SP
550 transition and upregulated the DNA methyltransferase *DNMT1*, which might be required for
551 maintenance methylation during proliferation (unpublished observations, data from
552 [134,161]).

553 Information on the role of miRNAs in $\gamma\delta$ lineage differentiation is similarly sparse. miRNA
554 profiling of human thymocytes indicated a downregulation of many miRNAs in ISP
555 thymocytes compared to bipotent progenitors, whereas few miRNAs were differentially
556 regulated in cells committing to the $\gamma\delta$ lineage [138]. Analysis of miRNA changes in
557 response to Notch signalling identified miR-17 as a direct Notch target and overexpression of
558 miR-17 in Artificial Thymic Organoid (ATO) cultures resulted in an increased $\gamma\delta:\alpha\beta$
559 thymocyte ratio. This resembles the effects of Notch signalling on $\alpha\beta$ vs. $\gamma\delta$ development and
560 miR-17 was indeed able to rescue Notch inhibition-induced defects in $\gamma\delta$ T cell
561 differentiation [138]. Mechanistically, miR-17 was found to inhibit the expression of the $\alpha\beta$
562 lineage transcription factor BCL11B. Although knockdown of miR-17 did not selectively
563 affect the $\gamma\delta$ lineage, the findings suggest a possible role of the miRNA miR-17 in promoting
564 $\gamma\delta$ over $\alpha\beta$ fate via the repression of BCL11B [138]. In contrast, the microRNA miR-181a
565 was found to have a negative effect on $\gamma\delta$ T cell differentiation through inhibition of Notch2
566 and MAP3K2 and a resulting Notch/MAPK signalling reduction [162], which is expected to
567 counteract $\gamma\delta$ lineage commitment.

568

569 **3.2 The fate decision window**

570 The bifurcation point of the $\alpha\beta$ and $\gamma\delta$ lineages and the window within which thymocytes are
571 bipotent and retain some alternate lineage potential have remained remarkably ill-defined. As
572 discussed above, rearrangement of the *TRD* and *TRG* loci commences very early in human
573 thymocytes and, assuming that fate is not intrinsically pre-programmed, cells should be able
574 to commit to the $\gamma\delta$ lineage as soon as they have successfully rearranged one *TRD* and *TRG*
575 allele each. The observation that the *TRB* locus is still in germline configuration or
576 incompletely rearranged in most $\gamma\delta$ T cells [49–51] suggests that many thymocytes in fact
577 adopt the $\gamma\delta$ fate before initiating the generation of a β -chain. This portrays the bifurcation
578 process as a sequence of decisions, where in the majority of cells the possibility of becoming
579 a $\gamma\delta$ T cell is tested first and only in case this is unsuccessful or too slow, do thymocytes
580 attempt to adopt the $\alpha\beta$ fate. Curiously, based on clonal cultures from CD34+ thymocytes it
581 was concluded that a sizeable fraction of cells already loses its bipotent properties around the
582 T lineage commitment step, but this may represent a side-effect of the OP9-DLL1 *in vitro*
583 culture system since partial inhibition of Notch signalling was shown to increase the
584 frequency of bipotent cells [101]. Two things can likely be responsible for extinguishing $\gamma\delta$
585 potential under physiological circumstances: biallelic out-of-frame rearrangements for *TRG*
586 or *TRD* or β -selection and concomitant commitment to the $\alpha\beta$ lineage. The timing of β -
587 selection has been a matter of debate, with different studies placing it in the ISP or DP stage
588 based on the expression of *RAG1/2*, *PTCRA*, CD3 and the TCR β -chain itself [48,149,163–
589 165]. It is therefore likely that β -selection does not coincide with a specific CD4/CD8 surface
590 profile [29,166] but can take place throughout the ISP and up until the CD4+CD8 $\alpha\beta$ + DP
591 stage. Consistent with this, it has been shown that $\gamma\delta$ lineage potential drops rapidly from the
592 ISP stage onwards. However, some $\gamma\delta$ T cells can still arise from ISP and CD3- DP
593 thymocytes in FTOCs and OP9 co-cultures [49,115], indicating an extensive window during
594 which thymocytes can adopt $\gamma\delta$ fate. Interestingly, a small number of DP TCR $\gamma\delta$ +CD1+ cells
595 also seem to give rise to CD3+TCR $\alpha\beta$ + thymocytes *in vitro* [115], which implies that
596 immature $\gamma\delta$ T cells still retain some $\alpha\beta$ lineage potential. Overall, thymocytes experience a

597 long period, during which cells can choose to commit to the $\alpha\beta$ or $\gamma\delta$ lineage, and the exact
598 decision point will vary immensely between individual cells. For this reason, novel single cell
599 approaches may prove useful to further investigate and quantify the lineage potential of
600 thymocytes throughout differentiation. Nevertheless, progenitors seem to start with a high
601 potential to adopt $\gamma\delta$ fate, which then gradually drops as the cells differentiate further, as
602 recently predicted based on single cell thymic data using the STEMNET algorithm [134].
603

604 **3.3 Thymic selection of $\gamma\delta$ T cells**

605 For the $\alpha\beta$ lineage, it is well established that cells undergo several selection steps that confirm
606 the functionality and lack of autoreactivity of their TCR. Whether a similar procedure takes
607 place in the $\gamma\delta$ lineage is not entirely clear. To our knowledge, no evidence has been
608 published supporting the presence of a negative selection mechanism in $\gamma\delta$ T cells [51] and it
609 is known that $\gamma\delta$ TCRs frequently recognise self-antigens. Peripheral tolerance mechanisms
610 most likely exist to prevent auto-reactivity [167], but this remains to be demonstrated. A
611 positive selection step similar to the $\alpha\beta$ lineage is unlikely to apply in $\gamma\delta$ T cells due to their
612 HLA independence. However, it has been speculated that TCR $\gamma\delta$ + thymocytes engage in
613 ligand-dependent TCR signalling, which could represent a mechanism to test antigen
614 specificity and promote the development of specific subsets as shown in mouse [168,169].
615 Analysis of human fetal $\gamma\delta$ T cells has indeed shown that these already exhibit a
616 phosphoantigen-reactive TCR repertoire, but since the enriched TCR CDR3 sequences
617 appear to be germline-encoded, it is unclear whether endogenous phosphoantigens are
618 responsible for the enrichment [170]. While it is certainly possible that $\gamma\delta$ thymocytes
619 respond to endogenous or exogenous antigens in the thymic environment, it has been
620 suggested that the $\gamma\delta$ TCR may be able to spontaneously dimerise and thereby induce TCR
621 signalling to promote $\gamma\delta$ lineage commitment and proliferation in a ligand-independent
622 manner, similar to the pre-TCR during β -selection [171,172]. However, $\gamma\delta$ TCR dimers have
623 so far only been demonstrated in human but not mouse [173], so this mechanism of action
624 remains speculative.
625

626 **4 Mature $\gamma\delta$ T cells in the human thymus**

627
628 The maturation of TCR $\gamma\delta$ + thymocytes can be traced based on several surface markers.
629 Upregulation of CD73 has been described as an indicator of full commitment to the $\gamma\delta$
630 lineage [138,174]. Moreover, like in the $\alpha\beta$ lineage, CD1 levels drop in mature $\gamma\delta$ T cells
631 whereas CD27 is upregulated [114] (Figure 1).
632

633 **4.1 Acquisition of $\gamma\delta$ T cell effector functions in the thymus**

634 For murine $\gamma\delta$ T cells, it is well known that the adoption of different effector phenotypes
635 already takes place in the thymus and mature $\gamma\delta$ T cells can be broadly grouped into IFN γ -
636 and IL17-producing subtypes [157,171,175–177]. This grouping does not directly apply to
637 human $\gamma\delta$ T cells as the vast majority are IFN producers and IL17-producing cells have been
638 shown to arise only under certain inflammatory conditions and in very small numbers
639 [178,179] (Table 1). Human paediatric $\gamma\delta$ thymocytes also seem more naïve compared to
640 peripheral blood $\gamma\delta$ T cells based on their surface marker profile, ability to produce TNF α and

641 IFN γ upon TCR stimulation, and cytolytic activity against leukemic cells [180]. On the other
642 hand, they can react to certain cytokine stimuli with proliferation and initiation of a cytotoxic
643 response [114,180], which indicates a higher level of maturity than observed in $\alpha\beta$ lineage
644 thymocytes. Their ability to develop into effector cells and carry out cytotoxic functions
645 without the requirement for TCR stimulation represents one of the key reasons why $\gamma\delta$ T cells
646 can be considered innate-like. IL7 plays an essential role in the induction of effector
647 differentiation in mouse thymocytes [181], but it is unable to accomplish this in human
648 thymic $\gamma\delta$ T cells [180].

649 Importantly, recent work from the Vermijlen lab was able to demonstrate that adoption of
650 effector function may occur in fetal thymic TCR $\gamma\delta^+$ cells. They found that the transcriptional
651 programme of CD1- $\gamma\delta$ T cells from fetal thymus and liver was comparable to activated T
652 and NK cells, which was not the case for postnatal $\gamma\delta$ thymocytes [54]. Moreover, fetal
653 thymic $\gamma\delta$ T cells were able to produce effector cytokines, such as IFN γ , TNF α and
654 granzymes, without the need for stimulation [54,182]. scRNA-seq analysis of fetal thymus
655 samples revealed effector programming of a considerable fraction of $\gamma\delta$ thymocytes and the
656 size of this subset was negatively correlated with gestational age [183]. In contrast, in
657 paediatric thymic effector programming of $\gamma\delta$ T cells was exceedingly rare and limited to a
658 minor subset of V γ 9+V δ 2+ cells [183]. This suggests that fetal and postnatal $\gamma\delta$ T cells in the
659 human thymus exhibit distinct differences with a prominent level of effector programming
660 before but not after birth.

661

662 **4.2 Development of human $\gamma\delta$ T cell subtypes**

663 Similarly to the age-dependency of effector pre-programming, different human $\gamma\delta$ subtypes
664 arise during distinct developmental windows throughout pre- and postnatal life. Mature $\gamma\delta$ T
665 cells are commonly distinguished based on *TRDV* usage with the main two subtypes being
666 V δ 2+ and V δ 2- $\gamma\delta$ T cells, which differ in their target antigens, adaptive vs. innate behaviour
667 and tissue localisation (reviewed in [167,184,185]). *TRDV2* most frequently pairs with
668 *TRGV9* and the resulting V γ 9+V δ 2+ T cells are the first $\gamma\delta$ T cells to arise in embryonic
669 development (Figure 4). This phosphoantigen-responsive subtype can be detected in the
670 embryonic liver as early as 5 wpc and shortly after from 8 wpc in the thymus [186,187],
671 where they represent the main $\gamma\delta$ T cell type until mid-gestation [54,55]. Consequently, they
672 also make up the majority of $\gamma\delta$ T cells in the fetal blood but there their frequencies
673 continuously decrease until birth [170,188,189], which has been attributed to their emigration
674 into various tissues in combination with reduced thymic output. Soon after birth, circulating
675 V γ 9+V δ 2+ cells start to expand rapidly in response to pathogen exposure and eventually
676 represent the predominant $\gamma\delta$ T subtype in the blood throughout childhood, adolescence and
677 adulthood [189–193] (Figure 4). It was long thought that circulating V γ 9+V δ 2+ cells are
678 exclusively fetal-derived and maintained by proliferation and clonal expansion [59,185,189],
679 but recent evidence has made a strong case for postnatal thymic development of V γ 9+V δ 2+
680 cells: Earlier studies claiming a complete absence of V γ 9+V δ 2+ thymocytes after birth
681 [59,180,187,189] were disproven by the discovery of a small population of *TRDV2/TRGV9*
682 co-expressing cells in the postnatal thymus [55], indicating the possibility of ongoing
683 differentiation of this cell type beyond the initial fetal wave. Moreover, V γ 9+V δ 2+ cells can
684 successfully regenerate after stem cell transplantation in adults [194,195], suggesting that

685 their development does not strictly require the fetal thymic environment. Finally, fetal and
686 postnatal V γ 9+V δ 2+ T cells in the blood show clear repertoire differences with divergence in
687 the use of *TRDJ1/2/3* [55,191,196] and age-correlated increase in the number of N insertions
688 in the γ - and δ -chain CDR3. Importantly, these differences are mirrored in the thymic
689 V γ 9+V δ 2+ repertoire at the corresponding developmental stage [55]. *In vitro* stimulation of
690 fetal V γ 9+V δ 2+ cells did not result in repertoire changes or selective expansion that would
691 support an exclusively fetal origin of peripheral V γ 9+V δ 2+ cells in adult blood [55]. Hence it
692 is likely that this cell type is continuously produced throughout life and contributes to the
693 maintenance of the peripheral V γ 9+V δ 2+ T cell pool. The observed differences in nucleotide
694 addition and CDR3 sequence length in fetally and postnatally generated V γ 9+V δ 2+ cells are
695 probably the result of different TdT levels throughout gestation [54,56]. This results in very
696 limited insertion of nucleotides during V(D)J recombination in early development and hence
697 in a highly invariant fetal repertoire [54]. This seems to be an intrinsic property of the
698 precursor cells and independent of the developmental environment since HSPCs derived from
699 fetal liver and cord/peripheral blood still exhibit differences in N insertions when cultured *in*
700 *vitro* under identical conditions [55] and fetal but not adult HSPCs can give rise to certain
701 invariant TCRs [54]. The invariant repertoire of fetal $\gamma\delta$ T cells has been associated with a
702 more innate-like character, which can represent a vital first-line defence in absence of a
703 mature adaptive immune system. Therefore, the deliberate downregulation of TdT in fetal
704 thymocytes might represent a protective mechanism against infections *in utero* and in infancy
705 when the $\alpha\beta$ lineage is still naïve [170,185,197,198].

706 A much smaller, less well-studied subgroup of V δ 2+ T cells uses γ -chains other than *TRGV9*
707 to assemble the $\gamma\delta$ TCR. These V γ 9-V δ 2+ cells possess a private TCR repertoire and are not
708 responsive to phosphoantigens, which suggests a more adaptive behaviour and thus higher
709 similarity to V δ 1+ rather than V γ 9+V δ 2+ T cells [196]. They represent the second wave of $\gamma\delta$
710 T cells in the human thymus and are the most abundant population at mid-gestation [54,55]
711 (Figure 4). In contrast, only low numbers of V γ 9-V δ 2+ cells are detected in the postnatal
712 thymus [54,55], which indicates that their differentiation may continue throughout life but
713 most likely at low frequencies. The proportion of V γ 9-V δ 2+ cells in the blood appears to be
714 negligible throughout fetal and postnatal life [54,170,188], which implies rapid migration to
715 their main sites of residence, for instance the subcutaneous adipose tissue [199].

716 The V δ 2- subset of $\gamma\delta$ T cells is mainly composed of V δ 1+ cells and smaller proportions of
717 V δ 3+ and V δ 5+ cells, all of which pair with a diverse mix of γ -chains. These $\gamma\delta$ T cells are
718 considered to be more adaptive-like and exhibit a private repertoire [167,195]. V δ 1+
719 thymocytes seem to be generated from mid-gestation onwards and remain the dominant
720 thymocyte population throughout late fetal, postnatal and adult life [54,189] (Figure 4). Their
721 emigration towards their main target tissues, e.g. gut, liver and epithelial sites, is evident from
722 increased V δ 1+ fractions in late fetal and cord blood [170,182,188,189], and high proportions
723 of V δ 1+ thymocytes postnatally combined with moderate frequencies in peripheral blood
724 suggest continuous thymic output after birth [54,188,200]. Similar to V γ 9+V δ 2+ cells, the
725 repertoire of V δ 1+ $\gamma\delta$ T seems to undergo age-related focussing due to pathogen exposure as
726 evident from the presence of few highly expanded clones in adult blood, which do not yet
727 occur in cord blood [195]. Of note, it has been shown in *in vitro* co-cultures that HSPCs
728 derived from fetal liver/thymus or cord/adult blood are intrinsically programmed to

729 preferentially give rise to V δ 2+ and V δ 1+ T cells, respectively [54], which suggests that
730 differences in the precursor cells rather than changes in the thymic environment are
731 responsible for the age-dependent development of $\gamma\delta$ subtypes.
732 Little is known about the thymic development of V δ 1-V δ 2- $\gamma\delta$ T cells but they were shown to
733 be relatively abundant specifically in late-fetal and neonatal blood, which suggests that this
734 subtype predominantly arises around birth [170,200] (Figure 4).
735 Curiously, effector programming of $\gamma\delta$ T cells in the fetal thymus was observed for both
736 V γ 9+V δ 2+ and non-V γ 9+V δ 2+ cells and no preference for a certain effector fate was
737 detected between the two subsets [183]. This is in contrast to observations in mice, where
738 different effector fates are normally associated with distinct TRGV usage. Furthermore, the
739 presence or absence of specific Notch ligands does not seem to affect the proportions of
740 V γ 9+, V δ 1+, V δ 2+ and V δ 3+ cells developing from human thymocytes [33], whereas mouse
741 $\gamma\delta$ effector subtypes exhibit varying dependence on Notch signalling activity [201]. This lack
742 of conservation in $\gamma\delta$ T cell subtypes and effector differentiation mechanisms between mouse
743 and human illustrates the need for further research into the processes that govern $\gamma\delta$ T cell
744 development specifically in the human context.

745

746 **5 Conclusion**

747 The existence of $\gamma\delta$ T cells has been known for close to 40 years and research efforts have
748 provided us with remarkable insights into the functional roles and modes of action of this
749 fascinating cell type. Yet the details underlying the development of $\gamma\delta$ T cells in the human
750 thymus are still incompletely understood. Only few signalling pathways have been linked
751 with $\gamma\delta$ lineage commitment and their contribution to $\gamma\delta$ differentiation remains ill-defined
752 due to their changing roles throughout development and the conflicting findings in mouse and
753 human (Table 1). Similarly, little is known about the transcription factors controlling
754 adoption of the $\gamma\delta$ fate. However, recent technological advances, such as the increasing
755 accessibility of single cell sequencing techniques and the vast improvements in *in vitro* gene
756 editing and iPSC-derived T cell differentiation, hold great promise and will undoubtedly be
757 extremely valuable to tackle the remaining open questions in this field of research.

758

759

760

761 **Acknowledgements**

762 We apologise to our colleagues whose work could not be cited due to space limitations. We
763 thank Jolien Van Hulle for helpful feedback and critical reading of the manuscript. This work
764 was supported by the Fund for Scientific Research Flanders, Ghent University and The Chan
765 Zuckerberg Initiative. Illustrations were created with BioRender.com.

766

767 **Declaration of interest**

768 The authors declare no conflicts of interest.

769

- 770 [1] W. Holtmeier, D. Kabelitz, $\gamma\delta$ T Cells Link Innate and Adaptive, *Chem Immunol*
771 *Allergy*. 86 (2005) 151–183.
- 772 [2] L.M.R. Ferreira, $\gamma\delta$ T Cells: Innately adaptive immune cells, *Int. Rev.*
773 *Immunol.* 32 (2013) 223–248. <https://doi.org/10.3109/08830185.2013.783831>.
- 774 [3] D. Vermijlen, D. Gatti, A. Kouzeli, T. Rus, M. Eberl, $\gamma\delta$ T cell responses: How many
775 ligands will it take till we know?, *Semin. Cell Dev. Biol.* 84 (2018) 75–86.
776 <https://doi.org/10.1016/j.semcdb.2017.10.009>.
- 777 [4] D. Kabelitz, R. Serrano, L. Kouakanou, C. Peters, S. Kalyan, Cancer immunotherapy
778 with $\gamma\delta$ T cells: many paths ahead of us, *Cell. Mol. Immunol.* 17 (2020) 925–939.
779 <https://doi.org/10.1038/s41423-020-0504-x>.
- 780 [5] W.K. Born, M.K. Aydintug, R.L. O’Brien, Diversity of $\gamma\delta$ T-cell antigens, *Cell. Mol.*
781 *Immunol.* 10 (2013) 13–20. <https://doi.org/10.1038/cmi.2012.45>.
- 782 [6] A.E. Simões, B. Di Lorenzo, B. Silva-Santos, Molecular determinants of target cell
783 recognition by human $\gamma\delta$ T cells, *Front. Immunol.* 9 (2018) 1–7.
784 <https://doi.org/10.3389/fimmu.2018.00929>.
- 785 [7] J. Saura-Esteller, M. de Jong, L.A. King, E. Ensing, B. Winograd, T.D. de Gruijl,
786 P.W.H.I. Parren, H.J. van der Vliet, Gamma Delta T-Cell Based Cancer
787 Immunotherapy: Past-Present-Future, *Front. Immunol.* 13 (2022) 1–11.
788 <https://doi.org/10.3389/fimmu.2022.915837>.
- 789 [8] J. Zeng, S.Y. Tang, S. Wang, Derivation of mimetic $\gamma\delta$ T cells endowed with cancer
790 recognition receptors from reprogrammed $\gamma\delta$ T cell, *PLoS One*. 14 (2019) 1–20.
791 <https://doi.org/10.1371/journal.pone.0216815>.
- 792 [9] Y. Zhou, M. Li, K. Zhou, J. Brown, T. Tsao, X. Cen, T. Husman, A. Bajpai, Z.S.
793 Dunn, L. Yang, Engineering-Induced Pluripotent Stem Cells for Cancer
794 Immunotherapy, *Cancers (Basel)*. 14 (2022) 2266.
795 <https://doi.org/10.3390/cancers14092266>.
- 796 [10] D. Watanabe, M. Koyanagi-Aoi, M. Taniguchi-Ikeda, Y. Yoshida, T. Azuma, T. Aoi,
797 The Generation of Human $\gamma\delta$ T Cell-Derived Induced Pluripotent Stem Cells from
798 Whole Peripheral Blood Mononuclear Cell Culture, *Stem Cells Transl. Med.* 7 (2018)
799 34–44. <https://doi.org/10.1002/sctm.17-0021>.
- 800 [11] M. Ciofani, J.C. Zúñiga-Pflücker, Determining $\gamma\delta$ versus $\alpha\beta$ T cell development, *Nat.*
801 *Rev. Immunol.* 10 (2010) 657–663. <https://doi.org/10.1038/nri2820>.
- 802 [12] A. Dutta, H. Venkataganesh, P.E. Love, Epigenetic regulation of T cell development,
803 *Int. Rev. Immunol.* (2021) 1–9. <https://doi.org/10.1080/08830185.2021.2022661>.
- 804 [13] T. Kreslavsky, M. Gleimer, A.I. Garbe, H. von Boehmer, $\alpha\beta$ versus $\gamma\delta$ fate choice:
805 Counting the T-cell lineages at the branch point, *Immunol. Rev.* 238 (2010) 169–181.
806 <https://doi.org/10.1111/j.1600-065X.2010.00947.x>.
- 807 [14] S.Y. Lee, J. Stadanlick, D.J. Kappes, D.L. Wiest, Towards a molecular understanding
808 of the differential signals regulating $\alpha\beta/\gamma\delta$ T lineage choice, *Semin. Immunol.* 22
809 (2010) 237–246. <https://doi.org/10.1016/j.smim.2010.04.008>.
- 810 [15] I. Prinz, B. Silva-Santos, D.J. Pennington, Functional development of $\gamma\delta$ T cells, *Eur.*
811 *J. Immunol.* 43 (2013) 1988–1994. <https://doi.org/10.1002/eji.201343759>.
- 812 [16] D.L. Wiest, A. V. Contreras, Recent advances in understanding the development and
813 function of $\gamma\delta$ T cells, *F1000Research*. 9 (2020) 306.

- 814 <https://doi.org/10.12688/f1000research.22161.1>.
- 815 [17] G.W. Wong, J.C. Zúñiga-Pflücker, $\gamma\delta$ and $\alpha\beta$ T cell lineage choice: Resolution by a
816 stronger sense of being, *Semin. Immunol.* 22 (2010) 228–236.
817 <https://doi.org/10.1016/j.smim.2010.04.005>.
- 818 [18] N. Xiong, D.H. Raulet, Development and selection of $\gamma\delta$ T cells, *Immunol. Rev.* 215
819 (2007) 15–31. <https://doi.org/10.1111/j.1600-065X.2006.00478.x>.
- 820 [19] P. Zarin, E.L.Y. Chen, T.S.H. In, M.K. Anderson, J.C. Zúñiga-Pflücker, Gamma delta
821 T-cell differentiation and effector function programming, TCR signal strength, when
822 and how much?, *Cell. Immunol.* 296 (2015) 70–75.
823 <https://doi.org/10.1016/j.cellimm.2015.03.007>.
- 824 [20] D.J. Pennington, B. Silva-Santos, A.C. Hayday, $\gamma\delta$ T cell development - having the
825 strength to get there, *Curr. Opin. Immunol.* 17 (2005) 108–115.
826 <https://doi.org/10.1016/j.coi.2005.01.009>.
- 827 [21] Q. Yang, J. Jeremiah Bell, A. Bhandoola, T-cell lineage determination, *Immunol. Rev.*
828 238 (2010) 12–22. <https://doi.org/10.1111/j.1600-065X.2010.00956.x>.
- 829 [22] T. Naito, H. Tanaka, Y. Naoe, I. Taniuchi, Transcriptional control of T-cell
830 development, *Int. Immunol.* 23 (2011) 661–668.
831 <https://doi.org/10.1093/intimm/dxr078>.
- 832 [23] U. Koch, F. Radtke, Mechanisms of T Cell Development and Transformation, *Annu.*
833 *Rev. Cell Dev. Biol.* 27 (2011) 539–562. [https://doi.org/10.1146/annurev-cellbio-](https://doi.org/10.1146/annurev-cellbio-092910-154008)
834 [092910-154008](https://doi.org/10.1146/annurev-cellbio-092910-154008).
- 835 [24] E. V Rothenberg, J.E. Moore, M.A. Yui, Launching the T-cell-lineage developmental
836 programme, *Nat. Rev. Immunol.* 8 (2008) 9–21. <https://doi.org/10.1038/nri2232>.
- 837 [25] W. Seo, I. Taniuchi, Transcriptional regulation of early T-cell development in the
838 thymus, *Eur. J. Immunol.* 46 (2016) 531–538. <https://doi.org/10.1002/eji.201545821>.
- 839 [26] M. Ciofani, J.C. Zúñiga-Pflücker, The thymus as an inductive site for T
840 lymphopoiesis., *Annu Rev Cell Dev Biol.* 23 (2007) 463–493.
841 <https://doi.org/10.1146/annurev.cellbio.23.090506.123547>.
- 842 [27] H. Hosokawa, E. V. Rothenberg, How transcription factors drive choice of the T cell
843 fate, *Nat. Rev. Immunol.* 21 (2021) 162–176. [https://doi.org/10.1038/s41577-020-](https://doi.org/10.1038/s41577-020-00426-6)
844 [00426-6](https://doi.org/10.1038/s41577-020-00426-6).
- 845 [28] H. Spits, B. Blom, A.-C. Jaleco, K. Weijer, M.C.M. Verschuren, J.J.M. Van Dongen,
846 M.H.M. Heemskerk, P.C.M. Res, Early stages in the development of human T, natural
847 killer and thymic dendritic cells, *Immunol. Rev.* 165 (1998) 75–86.
848 <https://doi.org/10.1111/j.1600-065X.1998.tb01231.x>.
- 849 [29] R. Vicente, L. Swainson, S. Marty-Grès, S.C. De Barros, S. Kinet, V.S. Zimmermann,
850 N. Taylor, Molecular and cellular basis of T cell lineage commitment, *Semin.*
851 *Immunol.* 22 (2010) 270–275. <https://doi.org/10.1016/j.smim.2010.04.016>.
- 852 [30] R. De Pooter, J.C. Zúñiga-Pflücker, T-cell potential and development in vitro: the
853 OP9-DL1 approach, *Curr. Opin. Immunol.* 19 (2007) 163–168.
854 <https://doi.org/10.1016/j.coi.2007.02.011>.
- 855 [31] E. V. Rothenberg, Single-cell insights into the hematopoietic generation of T-
856 lymphocyte precursors in mouse and human, *Exp. Hematol.* 95 (2021) 1–12.
857 <https://doi.org/10.1016/j.exphem.2020.12.005>.

- 858 [32] F. Weerkamp, M.R.M. Baert, M.H. Brugman, W.A. Dik, E.F.E. De Haas, T.P. Visser,
859 C.J.M. De Groot, G. Wagemaker, J.J.M. Van Dongen, F.J.T. Staal, Human thymus
860 contains multipotent progenitors with T/B lymphoid, myeloid, and erythroid lineage
861 potential, *Blood*. 107 (2006) 3131–3137. <https://doi.org/10.1182/blood-2005-08-3412>.
- 862 [33] I. Van de Walle, E. Waegemans, J. De Medts, G. De Smet, M. De Smedt, S.
863 Snauwaert, B. Vandekerckhove, T. Kerre, G. Leclercq, J. Plum, T. Gridley, T. Wang,
864 U. Koch, F. Radtke, T. Taghon, Specific notch receptor-ligand interactions control
865 human TCR- $\alpha\beta/\gamma\delta$ development by inducing differential notch signal strength, *J. Exp.*
866 *Med.* 210 (2013) 683–697. <https://doi.org/10.1084/jem.20121798>.
- 867 [34] I. Van De Walle, A.C. Dolens, K. Durinck, K. De Mulder, W. Van Loocke, S. Damle,
868 E. Waegemans, J. De Medts, I. Velghe, M. De Smedt, B. Vandekerckhove, T. Kerre, J.
869 Plum, G. Leclercq, E. V. Rothenberg, P. Van Vlierberghe, F. Speleman, T. Taghon,
870 GATA3 induces human T-cell commitment by restraining Notch activity and
871 repressing NK-cell fate, *Nat. Commun.* 7 (2016) 11171.
872 <https://doi.org/10.1038/ncomms11171>.
- 873 [35] V.G. De Yébenes, Y.R. Carrasco, A.R. Ramiro, M.L. Toribio, Identification of a
874 myeloid intrathymic pathway of dendritic cell development marked by expression of
875 the granulocyte macrophage-colony-stimulating factor receptor, *Blood*. 99 (2002)
876 2948–2956. <https://doi.org/10.1182/blood.V99.8.2948>.
- 877 [36] C. Márquez, C. Trigueros, E. Fernández, M.L. Toribio, The development of T and
878 non-T cell lineages from CD34+ human thymic precursors can be traced by the
879 differential expression of CD44, *J. Exp. Med.* 181 (1995) 475–483.
880 <https://doi.org/10.1084/jem.181.2.475>.
- 881 [37] N. Lefort, C. Benne, J.D. Lelièvre, C. Dorival, M. Balbo, S. Sakano, L. Coulombel, Y.
882 Lévy, Short exposure to Notch ligand Delta-4 is sufficient to induce T-cell
883 differentiation program and to increase the T cell potential of primary human CD34+
884 cells, *Exp. Hematol.* 34 (2006) 1720–1729.
885 <https://doi.org/10.1016/j.exphem.2006.08.007>.
- 886 [38] S. González-García, M. García-Peydró, E. Martín-Gayo, E. Ballestar, M. Esteller, R.
887 Bornstein, J.L. De La Pompa, A.A. Ferrando, M.L. Toribio, CSL-MAML-dependent
888 Notch1 signaling controls T lineage-specific IL-7R α gene expression in early human
889 thymopoiesis and leukemia, *J. Exp. Med.* 206 (2009) 779–791.
890 <https://doi.org/10.1084/jem.20081922>.
- 891 [39] M. García-Peydró, V.G. De Yébenes, M.L. Toribio, Notch1 and IL-7 Receptor
892 Interplay Maintains Proliferation of Human Thymic Progenitors while Suppressing
893 Non-T Cell Fates, *J. Immunol.* 177 (2006) 3711–3720.
894 <https://doi.org/10.4049/jimmunol.177.6.3711>.
- 895 [40] M. De Smedt, I. Hoebeke, K. Reynvoet, G. Leclercq, J. Plum, Different thresholds of
896 Notch signaling bias human precursor cells toward B-, NK-, monocytic/dendritic-, or
897 T-cell lineage in thymus microenvironment, *Blood*. 106 (2005) 3498–3506.
898 <https://doi.org/10.1182/blood-2005-02-0496>.
- 899 [41] M. García-Peydró, V.G. De Yébenes, M.L. Toribio, Sustained Notch1 signaling
900 instructs the earliest human intrathymic precursors to adopt a $\gamma\delta$ T-cell fate in fetal
901 thymus organ culture, *Blood*. 102 (2003) 2444–2451. [https://doi.org/10.1182/blood-](https://doi.org/10.1182/blood-2002-10-3261)
902 [2002-10-3261](https://doi.org/10.1182/blood-2002-10-3261).
- 903 [42] V.L. Ha, A. Luong, F. Li, D. Casero, J. Malvar, Y.M. Kim, R. Bhatia, G.M. Crooks, C.

- 904 Parekh, The T-ALL related gene BCL11B regulates the initial stages of human T-cell
905 differentiation, *Leukemia*. 31 (2017) 2503–2514. <https://doi.org/10.1038/leu.2017.70>.
- 906 [43] K. Canté-Barrett, R.D. Mendes, Y. Li, E. Vroegindeweyj, K. Pike-Overzet, T. Wabeke,
907 A.W. Langerak, R. Pieters, F.J.T. Staal, J.P.P. Meijerink, Loss of CD44dim expression
908 from early progenitor cells marks T-cell lineage commitment in the human thymus,
909 *Front. Immunol.* 8 (2017) 1–15. <https://doi.org/10.3389/fimmu.2017.00032>.
- 910 [44] C. Pallard, A.P.A. Stegmann, T. Van Kleffens, F. Smart, A. Venkitaraman, H. Spits,
911 Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-
912 mediated development of human thymocyte precursors, *Immunity*. 10 (1999) 525–535.
913 [https://doi.org/10.1016/S1074-7613\(00\)80052-7](https://doi.org/10.1016/S1074-7613(00)80052-7).
- 914 [45] A. Puel, S.F. Ziegler, R.H. Buckley, W.J. Leonard, Defective IL7R expression in T-
915 B+NK+ severe combined immunodeficiency, *Nat. Genet.* 20 (1998) 394–397.
916 <https://doi.org/10.1038/3877>.
- 917 [46] W.A. Dik, K. Pike-Overzet, F. Weerkamp, D. De Ridder, E.F.E. De Haas, M.R.M.
918 Baert, P. Van Der Spek, E.E.L. Koster, M.J.T. Reinders, J.J.M. Van Dongen, A.W.
919 Langerak, F.J.T. Staal, New insights on human T cell development by quantitative T
920 cell receptor gene rearrangement studies and gene expression profiling, *J. Exp. Med.*
921 201 (2005) 1715–1723. <https://doi.org/10.1084/jem.20042524>.
- 922 [47] S. Ktorza, S. Sarun, F. Rieux-Laucat, J.-P. de Villartay, P. Debré, C. Schmitt, CD34-
923 positive early human thymocytes: T cell receptor and cytokine receptor gene
924 expression, *Eur. J. Immunol.* 25 (1995) 2471–2478.
925 <https://doi.org/https://doi.org/10.1002/eji.1830250910>.
- 926 [48] B. Blom, M.C.M. Verschuren, M.H.M. Heemskerk, A.Q. Bakker, E.J. Van Gastel-
927 Mol, I.L.M. Wolvers-Tettero, J.J.M. Van Dongen, H. Spits, TCR Gene
928 Rearrangements and Expression of the Pre-T Cell Receptor Complex During Human
929 T-Cell Differentiation, *Blood*. 93 (1999) 3033–3043.
930 <https://doi.org/10.1182/blood.v93.9.3033>.
- 931 [49] M.L. Joachims, J.L. Chain, S.W. Hooker, C.J. Knott-Craig, L.F. Thompson, Human $\alpha\beta$
932 and $\gamma\delta$ Thymocyte Development: TCR Gene Rearrangements, Intracellular TCR β
933 Expression, and $\gamma\delta$ Developmental Potential—Differences between Men and Mice, *J.*
934 *Immunol.* 176 (2006) 1543–1552. <https://doi.org/10.4049/jimmunol.176.3.1543>.
- 935 [50] C. Couedel, E. Lippert, K. Bernardeau, M. Bonneville, F. Davodeau, Allelic Exclusion
936 at the TCR δ Locus and Commitment to $\gamma\delta$ Lineage: Different Modalities Apply to
937 Distinct Human $\gamma\delta$ Subsets, *J. Immunol.* 172 (2004) 5544–5552.
938 <https://doi.org/10.4049/jimmunol.172.9.5544>.
- 939 [51] A.M. Sherwood, C. Desmarais, R.J. Livingston, J. Andriesen, M. Haussler, C.S.
940 Carlson, H. Robins, Deep sequencing of the human TCR γ and TCR β repertoires
941 suggests that TCR β rearranges after $\alpha\beta$ and $\gamma\delta$ T cell commitment, *Sci. Transl. Med.* 3
942 (2011) 1–8. <https://doi.org/10.1126/scitranslmed.3002536>.
- 943 [52] M.S. Krangel, H. Yssel, C. Brocklehurst, H. Spits, A distinct wave of human T cell
944 receptor γ/δ lymphocytes in the early fetal thymus: Evidence for controlled gene
945 rearrangement and cytokine Production, *J. Exp. Med.* 172 (1990) 847–859.
946 <https://doi.org/10.1084/jem.172.3.847>.
- 947 [53] J. Borst, A. Wicherink, J.J.M. Van Dongen, E. De Vries, W.M. Comans-Bitter, F.
948 Wassenaar, P. Van Den Elsen, Non-random expression of T cell receptor γ and δ

- 949 variable gene segments in functional T lymphocyte clones from human peripheral
950 blood, *Eur. J. Immunol.* 19 (1989) 1559–1568. <https://doi.org/10.1002/eji.1830190907>.
- 951 [54] P. Tieppo, M. Papadopoulou, D. Gatti, N. McGovern, J.K.Y. Chan, F. Gosselin, G.
952 Goetgeluk, K. Weening, L. Ma, N. Dauby, A. Cogan, C. Donner, F. Ginhoux, B.
953 Vandekerckhove, D. Vermijlen, The human fetal thymus generates invariant effector
954 $\gamma\delta$ T cells, *J. Exp. Med.* 217 (2020) e20190580.
955 https://doi.org/10.1084/jem_20190580.
- 956 [55] M. Papadopoulou, P. Tieppo, N. McGovern, F. Gosselin, J.K.Y. Chan, G. Goetgeluk,
957 N. Dauby, A. Cogan, C. Donner, F. Ginhoux, B. Vandekerckhove, D. Vermijlen, TCR
958 Sequencing Reveals the Distinct Development of Fetal and Adult Human V γ 9V δ 2 T
959 Cells, *J. Immunol.* 203 (2019) 1468–1479. <https://doi.org/10.4049/jimmunol.1900592>.
- 960 [56] M. Bodger, G. Janossy, F. Bollum, G. Burford, A. Hoffbrand, The ontogeny of
961 terminal deoxynucleotidyl transferase positive cells in the human fetus, *Blood.* 61
962 (1983) 1125–1131. <https://doi.org/10.1182/blood.v61.6.1125.1125>.
- 963 [57] Y. Zhang, D. Cado, D.M. Asarnow, T. Komori, F.W. Alt, D.H. Raullet, J.P. Allison,
964 The role of short homology repeats and TdT in generation of the invariant $\gamma\delta$ antigen
965 receptor repertoire in the fetal thymus, *Immunity.* 3 (1995) 439–447.
966 [https://doi.org/10.1016/1074-7613\(95\)90173-6](https://doi.org/10.1016/1074-7613(95)90173-6).
- 967 [58] V. Asnafi, K. Beldjord, E. Boulanger, B. Comba, P. Le Tuteur, M.-H. Estienne, F.
968 Davi, J. Landman-Parker, P. Quartier, A. Buzyn, E. Delabesse, F. Valensi, E.
969 Macintyre, Analysis of TCR, pT α , and RAG-1 in T-acute lymphoblastic leukemias
970 improves understanding of early human T-lymphoid lineage commitment, *Blood.* 101
971 (2003) 2693–2703. <https://doi.org/10.1182/blood-2002-08-2438>.
- 972 [59] G. Casorati, G. De Libero, A. Lanzavecchia, N. Migonet, Molecular Analysis of
973 Human γ/δ + Clones from Thymus and Peripheral Blood, *J. Exp. Med.* 170 (1989)
974 1521–1535.
- 975 [60] F. Davodeau, M.-A. Peyrat, I. Houde, M.-M. Hallet, G. De Libero, H. Vié, M.
976 Bonneville, Surface Expression of Two Distinct Functional Antigen Receptors on
977 Human $\gamma\delta$ T Cells, *Science* (80-.). 260 (1993) 1800–1802.
- 978 [61] K.R. Solomon, M.S. Krangel, J. McLean, M.B. Brenner, H. Band, Human T cell
979 receptor- γ and - δ chain pairing analyzed by transfection of a T cell receptor- δ negative
980 mutant cell line, *J. Immunol.* 144 (1990) 1120–1126.
981 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2136897%5Cnhttp://www.jimmunol.org/content/144/3/1120.full.pdf.
- 982
- 983 [62] L. Boucontet, M. Grana, P.M. Alzari, P. Pereira, Mechanisms determining cell
984 membrane expression of different $\gamma\delta$ TCR chain pairings, *Eur. J. Immunol.* 39 (2009)
985 1937–1946. <https://doi.org/10.1002/eji.200939345>.
- 986 [63] M.A. Peyrat, F. Davodeau, I. Houde, F. Romagné, A. Necker, C. Leget, J.P. Cervoni,
987 N. Cerf-Bensussan, H. Vié, M. Bonneville, H.M. M, Repertoire analysis of human
988 peripheral blood lymphocytes using a human V δ 3 region-specific monoclonal
989 antibody, *J. Immunol.* 155 (1995) 3060–3067.
- 990 [64] L. Boucontet, N. Sepúlveda, J. Carneiro, P. Pereira, Mechanisms Controlling
991 Termination of V-J Recombination at the TCR γ Locus: Implications for Allelic and
992 Isotypic Exclusion of TCR γ Chains, *J. Immunol.* 174 (2005) 3912–3919.
993 <https://doi.org/10.4049/jimmunol.174.7.3912>.

- 994 [65] I. Ferrero, A. Wilson, F. Beermann, W. Held, H.R. MacDonald, T cell receptor
 995 specificity is critical for the development of epidermal $\gamma\delta$ T cells, *J. Exp. Med.* 194
 996 (2001) 1473–1483. <https://doi.org/10.1084/jem.194.10.1473>.
- 997 [66] B.P. Sleckman, B. Khor, R. Monroe, F.W. Alt, Assembly of productive T cell receptor
 998 δ variable region genes exhibits allelic inclusion, *J. Exp. Med.* 188 (1998) 1465–1471.
 999 <https://doi.org/10.1084/jem.188.8.1465>.
- 1000 [67] N.B. Perumal, T.W. Kenniston, D.J. Tweardy, K.F. Dyer, R. Hoffman, J. Peschon,
 1001 P.M. Appasamy, TCR- γ genes are rearranged but not transcribed in IL-7R α -deficient
 1002 mice., *J. Immunol.* 158 (1997) 5744–5750.
 1003 <http://www.ncbi.nlm.nih.gov/pubmed/9190924>.
- 1004 [68] K. Maki, S. Sunaga, K. Ikuta, The V-J recombination of T cell receptor- γ genes is
 1005 blocked in interleukin-7 receptor-deficient mice, *J. Exp. Med.* 184 (1996) 2423–2427.
 1006 <https://doi.org/10.1084/jem.184.6.2423>.
- 1007 [69] S.K. Durum, S. Candèias, H. Nakajima, W.J. Leonard, A.M. Baird, L.J. Berg, K.
 1008 Muegge, Interleukin 7 receptor control of T cell receptor γ gene rearrangement: Role
 1009 of receptor-associated chains and locus accessibility, *J. Exp. Med.* 188 (1998) 2233–
 1010 2241. <https://doi.org/10.1084/jem.188.12.2233>.
- 1011 [70] S.-K. Ye, K. Maki, T. Kitamura, S. Sunaga, K. Akashi, J. Domen, I.L. Weissman, T.
 1012 Honjo, K. Ikuta, Induction of germline transcription in the TCR γ locus by Stat5:
 1013 Implications for accessibility control by the IL-7 receptor, *Immunity.* 11 (1999) 213–
 1014 223. [https://doi.org/10.1016/S1074-7613\(00\)80096-5](https://doi.org/10.1016/S1074-7613(00)80096-5).
- 1015 [71] M.S. Schlissel, S.D. Durum, K. Muegge, The interleukin 7 receptor is required for T
 1016 cell receptor γ locus accessibility to the V(D)J recombinase, *J. Exp. Med.* 191 (2000)
 1017 1045–1050. <https://doi.org/10.1084/jem.191.6.1045>.
- 1018 [72] J. Kang, M. Coles, D.H. Raulet, Defective development of γ/δ T cells in interleukin 7
 1019 receptor- deficient mice is due to impaired expression of T cell receptor γ genes, *J.*
 1020 *Exp. Med.* 190 (1999) 973–982. <https://doi.org/10.1084/jem.190.7.973>.
- 1021 [73] K. Wagatsuma, S. Tani-ichi, B. Liang, S. Shitara, K. Ishihara, M. Abe, H. Miyachi, S.
 1022 Kitano, T. Hara, M. Nanno, H. Ishikawa, K. Sakimura, M. Nakao, H. Kimura, K.
 1023 Ikuta, STAT5 Orchestrates Local Epigenetic Changes for Chromatin Accessibility and
 1024 Rearrangements by Direct Binding to the TCR γ Locus, *J. Immunol.* 195 (2015) 1804–
 1025 1814. <https://doi.org/10.4049/jimmunol.1302456>.
- 1026 [74] S.K. Ye, Y. Agata, H.-C. Lee, H. Kurooka, T. Kitamura, A. Shimizu, T. Honjo, K.
 1027 Ikuta, The IL-7 receptor controls the accessibility of the TCR γ locus by Stat5 and
 1028 histone acetylation, *Immunity.* 15 (2001) 813–823. [https://doi.org/10.1016/S1074-7613\(01\)00230-8](https://doi.org/10.1016/S1074-7613(01)00230-8).
- 1030 [75] P.M. Appasamy, T.W. Kenniston Jr, Y. Weng, E.C. Holt, J. Kost, W.H. Chambers,
 1031 Interleukin 7-induced expression of specific T cell receptor γ variable region genes in
 1032 murine fetal liver cultures, *J. Exp. Med.* 178 (1993) 2201–2206.
 1033 <https://doi.org/10.1084/jem.178.6.2201>.
- 1034 [76] J. Kang, B. DiBenedetto, K. Narayan, H. Zhao, S.D. Der, C.A. Chambers, STAT5 Is
 1035 Required for Thymopoiesis in a Development Stage-Specific Manner, *J. Immunol.* 173
 1036 (2004) 2307–2314. <https://doi.org/10.4049/jimmunol.173.4.2307>.
- 1037 [77] S. Tani-Ichi, M. Satake, K. Ikuta, Activation of the mouse TCR γ enhancers by STAT5,
 1038 *Int. Immunol.* 21 (2009) 1079–1088. <https://doi.org/10.1093/intimm/dxp073>.

- 1039 [78] H.-C. Lee, S.-K. Ye, T. Honjo, K. Ikuta, Induction of Germline Transcription in the
1040 Human TCR γ Locus by STAT5, *J. Immunol.* 167 (2001) 320–326.
1041 <https://doi.org/10.4049/jimmunol.167.1.320>.
- 1042 [79] A. Lev, A.J. Simon, O. Barel, E. Eyal, E. Glick-Saar, O. Nayshool, O. Birk, T.
1043 Stauber, A. Hochberg, A. Broides, S. Almashanu, A. Hendel, Y.N. Lee, R. Somech,
1044 Reduced function and diversity of T cell repertoire and distinct clinical course in
1045 patients with IL7RA mutation, *Front. Immunol.* 10 (2019) 1–13.
1046 <https://doi.org/10.3389/fimmu.2019.01672>.
- 1047 [80] X. Cao, E.W. Shores, J. Hu-Li, M.R. Anver, B.L. Kelsail, S.M. Russell, J. Drago, M.
1048 Noguchi, A. Grinberg, E.T. Bloom, W.E. Paul, S.I. Katz, P.E. Love, W.J. Leonard,
1049 Defective lymphoid development in mice lacking expression of the common cytokine
1050 receptor γ chain, *Immunity.* 2 (1995) 223–238. [https://doi.org/10.1016/1074-](https://doi.org/10.1016/1074-7613(95)90047-0)
1051 [7613\(95\)90047-0](https://doi.org/10.1016/1074-7613(95)90047-0).
- 1052 [81] S.Y. Park, K. Saijo, T. Takahashi, M. Osawa, H. Arase, N. Hirayama, K. Miyake, H.
1053 Nakauchi, T. Shirasawa, T. Saito, Developmental defects of lymphoid cells in Jak3
1054 kinase-deficient mice, *Immunity.* 3 (1995) 771–782. [https://doi.org/10.1016/1074-](https://doi.org/10.1016/1074-7613(95)90066-7)
1055 [7613\(95\)90066-7](https://doi.org/10.1016/1074-7613(95)90066-7).
- 1056 [82] A. Rodriguez-Caparrros, S. Tani-ichi, A. Casal, J. Lopez-Ros, C. Suñe, K. Ikuta, C.
1057 Hernandez-Munain, Interleukin-7 receptor signaling is crucial for enhancer-dependent
1058 TCR δ germline transcription mediated through STAT5 recruitment, *Front. Immunol.*
1059 13 (2022) 943510. <https://doi.org/10.3389/fimmu.2022.943510>.
- 1060 [83] A.-S. Wiekmeijer, K. Pike-Overzet, H. Ijspeert, M.H. Brugman, I.L.M. Wolvers-
1061 Tettero, A.C. Lankester, R.G.M. Bredius, J.J.M. Van Dongen, W.E. Fibbe, A.W.
1062 Langerak, M. Van Der Burg, F.J.T. Staal, Identification of checkpoints in human T-
1063 cell development using severe combined immunodeficiency stem cells, *J. Allergy Clin.*
1064 *Immunol.* 137 (2016) 517–526. <https://doi.org/10.1016/j.jaci.2015.08.022>.
- 1065 [84] M. Nozaki, K. Wakae, N. Tamaki, S. Sakamoto, K. Ohnishi, T. Uejima, N. Minato, I.
1066 Yanagihara, Y. Agata, Regulation of TCR V γ 2 gene rearrangement by the helix-loop-
1067 helix protein, E2A, *Int. Immunol.* 23 (2011) 297–305.
1068 <https://doi.org/10.1093/intimm/dxr005>.
- 1069 [85] G. Bain, W.J. Romanow, K. Albers, W.L. Havran, C. Murre, Positive and negative
1070 regulation of V(D)J recombination by the E2A proteins, *J. Exp. Med.* 189 (1999) 289–
1071 300. <https://doi.org/10.1084/jem.189.2.289>.
- 1072 [86] A.W. Langerak, I.L.M. Wolvers-Tettero, E.J. Van Gastel-Mol, M.E.C.M. Oud, J.J.M.
1073 Van Dongen, Basic helix-loop-helix proteins E2A and HEB induce immature T-cell
1074 receptor rearrangements in nonlymphoid cells, *Blood.* 98 (2001) 2456–2465.
1075 <https://doi.org/10.1182/blood.V98.8.2456>.
- 1076 [87] J.K. Ghosh, W.J. Romanow, C. Murre, Induction of a diverse T cell receptor γ/δ
1077 repertoire by the helix-loop-helix proteins E2A and HEB in nonlymphoid cells, *J. Exp.*
1078 *Med.* 193 (2001) 769–775. <https://doi.org/10.1084/jem.193.6.769>.
- 1079 [88] J. Roels, J. Van Hulle, M. Lavaert, A. Kuchmiy, S. Strubbe, T. Putteman, B.
1080 Vandekerckhove, G. Leclercq, F. Van Nieuwerburgh, L. Boehme, T. Taghon,
1081 Transcriptional dynamics and epigenetic regulation of E and ID protein encoding
1082 genes during human T cell development, *Front. Immunol.* (2022) 1–24.
1083 <https://doi.org/10.3389/fimmu.2022.960918>.

- 1084 [89] M. Schlissel, A. Voronova, D. Baltimore, Helix-loop-helix transcription factor E47
1085 activates germ-line immunoglobulin heavy-chain gene transcription and rearrangement
1086 in a pre-T-cell line, *Genes Dev.* 5 (1991) 1367–1376.
1087 <https://doi.org/10.1101/gad.5.8.1367>.
- 1088 [90] K. Miyazaki, H. Watanabe, G. Yoshikawa, K. Chen, R. Hidaka, Y. Aitani, K. Osawa,
1089 R. Takeda, Y. Ochi, S. Tani-Ichi, T. Uehata, O. Takeuchi, K. Ikuta, S. Ogawa, G.
1090 Kondoh, Y.C. Lin, H. Ogata, M. Miyazaki, The transcription factor E2A activates
1091 multiple enhancers that drive Rag expression in developing T and B cells, *Sci.*
1092 *Immunol.* 5 (2020). <https://doi.org/10.1126/sciimmunol.abb1455>.
- 1093 [91] A. Rodríguez-Caparrós, V. García, Á. Casal, J. López-Ros, A. García-Mariscal, S.
1094 Tani-ichi, K. Ikuta, C. Hernández-Munain, Notch Signaling Controls Transcription via
1095 the Recruitment of RUNX1 and MYB to Enhancers during T Cell Development, *J.*
1096 *Immunol.* 202 (2019) 2460–2472. <https://doi.org/10.4049/jimmunol.1801650>.
- 1097 [92] C. Hernandez-Munain, M.S. Krangel, Regulation of the T-cell receptor δ enhancer by
1098 functional cooperation between c-Myb and core-binding factors, *Mol. Cell. Biol.* 14
1099 (1994) 473–483. <https://doi.org/10.1128/mcb.14.1.473-483.1994>.
- 1100 [93] C. Hernandez-Munain, M.S. Krangel, c-Myb and core-binding factor/PEBP2 display
1101 functional synergy but bind independently to adjacent sites in the T-cell receptor δ
1102 enhancer, *Mol. Cell. Biol.* 15 (1995) 3090–3099.
1103 <https://doi.org/10.1128/mcb.15.6.3090>.
- 1104 [94] C. Hernández Munain, P. Lauzurica, M.S. Krangel, Regulation of T cell receptor δ
1105 gene rearrangement by c-Myb, *J. Exp. Med.* 183 (1996) 289–293.
1106 <https://doi.org/10.1084/jem.185.7.1193>.
- 1107 [95] C. Hernández-Munain, M.S. Krangel, Distinct Roles for c-Myb and Core Binding
1108 Factor/Polyoma Enhancer-Binding Protein 2 in the Assembly and Function of a
1109 Multiprotein Complex on the TCR δ Enhancer In Vivo, *J. Immunol.* 169 (2002) 4362–
1110 4369. <https://doi.org/10.4049/jimmunol.169.8.4362>.
- 1111 [96] Y.H. Hsiang, J.P. Goldman, D.H. Raulet, The role of c-Myb or a related factor in
1112 regulating the T cell receptor gamma gene enhancer, *J Immunol.* 154 (1995) 5195–
1113 5204.
1114 [http://www.ncbi.nlm.nih.gov/pubmed/7730626%5Cnhttp://www.jimmunol.org/content/](http://www.ncbi.nlm.nih.gov/pubmed/7730626%5Cnhttp://www.jimmunol.org/content/154/10/5195.full.pdf)
1115 [/154/10/5195.full.pdf](http://www.jimmunol.org/content/154/10/5195.full.pdf).
- 1116 [97] J. Marine, A. Winoto, The human enhancer-binding protein Gata3 binds to several T-
1117 cell receptor regulatory elements, *Proc. Natl. Acad. Sci. U. S. A.* 88 (1991) 7284–
1118 7288. <https://doi.org/10.1073/pnas.88.16.7284>.
- 1119 [98] V. Joulin, D. Bories, J.F. Eléouet, M.C. Labastie, S. Chrétien, M.G. Mattéi, P.H.
1120 Roméo, A T-cell specific TCR δ DNA binding protein is a member of the human
1121 GATA family, *EMBO J.* 10 (1991) 1809–1816. [https://doi.org/10.1002/j.1460-](https://doi.org/10.1002/j.1460-2075.1991.tb07706.x)
1122 [2075.1991.tb07706.x](https://doi.org/10.1002/j.1460-2075.1991.tb07706.x).
- 1123 [99] L.J. Ko, M. Yamamoto, M.W. Leonard, K.M. George, P. Ting, J.D. Engel, Murine and
1124 human T-lymphocyte GATA-3 factors mediate transcription through a cis-regulatory
1125 element within the human T-cell receptor δ gene enhancer, *Mol. Cell. Biol.* 11 (1991)
1126 2778–2784. <https://doi.org/10.1128/mcb.11.5.2778-2784.1991>.
- 1127 [100] C. Hernández-Munain, Recent insights into the transcriptional control of the Tcr α /Tcr δ
1128 locus by distant enhancers during the development of T-lymphocytes, *Transcription.* 6

- 1129 (2015) 65–73. <https://doi.org/10.1080/21541264.2015.1078429>.
- 1130 [101] I. Van de Walle, G. De Smet, M. De Smedt, B. Vandekerckhove, G. Leclercq, J. Plum,
1131 T. Taghon, An early decrease in Notch activation is required for human TCR- $\alpha\beta$
1132 lineage differentiation at the expense of TCR- $\gamma\delta$ T cells, *Blood*. 113 (2009) 2988–
1133 2998. <https://doi.org/10.1182/blood-2008-06-164871>.
- 1134 [102] L. Nie, M. Xu, A. Vladimirova, X.-H. Sun, Notch-induced E2A ubiquitination and
1135 degradation are controlled by MAP kinase activities, *EMBO J.* 22 (2003) 5780–5792.
1136 <https://doi.org/10.1093/emboj/cdg567>.
- 1137 [103] P. Ordentlich, A. Lin, C.-P. Shen, C. Blaumueller, K. Matsuno, S. Artavanis-Tsakonas,
1138 T. Kadesch, Notch Inhibition of E47 Supports the Existence of a Novel Signaling
1139 Pathway, *Mol. Cell. Biol.* 18 (1998) 2230–2239.
1140 <https://doi.org/10.1128/mcb.18.4.2230>.
- 1141 [104] S. Reynaud-Deonauth, H. Zhang, A. Afouda, S. Taillefert, P. Beatus, M. Kloc, L.D.
1142 Etkin, J. Fischer-Lougheed, G. Spohr, Notch signaling is involved in the regulation of
1143 Id3 gene transcription during *Xenopus* embryogenesis, *Differentiation*. 69 (2002) 198–
1144 208. <https://doi.org/10.1046/j.1432-0436.2002.690413.x>.
- 1145 [105] T. Taghon, E. Waegemans, I. Van de Walle, Notch Signaling During Human T cell
1146 Development, in: F. Radtke (Ed.), *Notch Regul. Immune Syst.*, Springer, 2012: pp.
1147 75–97. <https://doi.org/10.3109/08820137709055812>.
- 1148 [106] G. Bain, C.B. Cravatt, C. Loomans, J. Alberola-Ila, S.M. Hedrick, C. Murre,
1149 Regulation of the helix-loop-helix proteins, E2A and Id3, by the Ras-ERK MAPK
1150 cascade, *Nat. Immunol.* 2 (2001) 165–171. <https://doi.org/10.1038/84273>.
- 1151 [107] L. Riera-Sans, A. Behrens, Regulation of $\alpha\beta/\gamma\delta$ T Cell Development by the Activator
1152 Protein 1 Transcription Factor c-Jun, *J. Immunol.* 178 (2007) 5690–5700.
1153 <https://doi.org/10.4049/jimmunol.178.9.5690>.
- 1154 [108] L. Bruno, H.J. Fehling, H. Von Boehmer, The $\alpha\beta$ T cell receptor can replace the $\gamma\delta$
1155 receptor in the development of $\gamma\delta$ lineage cells, *Immunity*. 5 (1996) 343–352.
1156 [https://doi.org/10.1016/S1074-7613\(00\)80260-5](https://doi.org/10.1016/S1074-7613(00)80260-5).
- 1157 [109] T. Egawa, T. Kreslavsky, D.R. Littman, H. von Boehmer, Lineage diversion of T cell
1158 receptor transgenic thymocytes revealed by lineage fate mapping, *PLoS One*. 3 (2008)
1159 e1512. <https://doi.org/10.1371/journal.pone.0001512>.
- 1160 [110] K. Terrence, C.P. Pavlovich, E.O. Matechak, B.J. Fowlkes, Premature expression of T
1161 cell receptor (TCR) $\alpha\beta$ suppresses TCR $\gamma\delta$ gene rearrangement but permits development
1162 of $\gamma\delta$ lineage T cells, *J. Exp. Med.* 192 (2000) 537–548.
1163 <https://doi.org/10.1084/jem.192.4.537>.
- 1164 [111] D.J. Pennington, B. Silva-Santos, J. Shires, E. Theodoridis, C. Pollitt, E.L. Wise, R.E.
1165 Tigelaar, M.J. Owen, A.C. Hayday, The inter-relatedness and interdependence of
1166 mouse T cell receptor $\gamma\delta^+$ and $\alpha\beta^+$ cells, *Nat. Immunol.* 4 (2003) 991–998.
1167 <https://doi.org/10.1038/ni979>.
- 1168 [112] A.I. Garbe, A. Krueger, F. Gounari, J.C. Zúñiga-Pflücker, H. Von Boehmer,
1169 Differential synergy of Notch and T cell receptor signaling determines $\alpha\beta$ versus $\gamma\delta$
1170 lineage fate, *J. Exp. Med.* 203 (2006) 1579–1590.
1171 <https://doi.org/10.1084/jem.20060474>.
- 1172 [113] M.C. Haks, J.M. Lefebvre, J.P.H. Lauritsen, M. Carleton, M. Rhodes, T. Miyazaki,

- 1173 D.J. Kappes, D.L. Wiest, Attenuation of $\gamma\delta$ TCR signaling efficiently diverts
1174 thymocytes to the $\alpha\beta$ lineage, *Immunity*. 22 (2005) 595–606.
1175 <https://doi.org/10.1016/j.immuni.2005.04.003>.
- 1176 [114] F. Offner, K. Van Beneden, V. Debacker, D. Vanhecke, B. Vandekerckhove, J. Plum,
1177 G. Leclercq, Phenotypic and functional maturation of TCR $\gamma\delta$ cells in the human
1178 thymus, *J. Immunol.* 158 (1997) 4634–4641. [https://doi.org/10.1016/s0165-](https://doi.org/10.1016/s0165-2478(97)87771-1)
1179 [2478\(97\)87771-1](https://doi.org/10.1016/s0165-2478(97)87771-1).
- 1180 [115] S. Van Coppennolle, S. Vanhee, G. Verstichel, S. Snauwaert, A. Van Der Spek, I.
1181 Velghe, M. Sinnesael, M.H. Heemskerk, T. Taghon, G. Leclercq, J. Plum, A.W.
1182 Langerak, T. Kerre, B. Vandekerckhove, Notch induces human T-cell receptor $\gamma\delta$ +
1183 thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8
1184 double-positive pathway, *Leukemia*. 26 (2012) 127–138.
1185 <https://doi.org/10.1038/leu.2011.324>.
- 1186 [116] N.A. Spidale, K. Sylvia, K. Narayan, B. Miu, M. Frascoli, H.J. Melichar, W. Zhihao, J.
1187 Kisielow, A. Palin, T. Serwold, P. Love, M. Kobayashi, M. Yoshimoto, N. Jain, J.
1188 Kang, Interleukin-17-Producing $\gamma\delta$ T Cells Originate from SOX13+ Progenitors that
1189 Are Independent of $\gamma\delta$ TCR Signaling, *Immunity*. 49 (2018) 857–872.
1190 <https://doi.org/10.1016/j.immuni.2018.09.010>.
- 1191 [117] H. Melichar, K. Narayan, S.O. Der, Y. Hiraoka, N. Gardiol, G. Jeannet, W. Held, C.A.
1192 Chambers, J. Kang, Regulation of $\gamma\delta$ versus $\alpha\beta$ T lymphocyte differentiation by the
1193 transcription factor SOX13, *Science* (80-.). 315 (2007) 230–233.
1194 <https://doi.org/10.1126/science.1135344>.
- 1195 [118] J. Kang, A. Volkmann, D.H. Raulet, Evidence that $\gamma\delta$ versus $\alpha\beta$ T cell fate
1196 determination is initiated independently of T cell receptor signaling, *J. Exp. Med.* 193
1197 (2001) 689–698. <https://doi.org/10.1084/jem.193.6.689>.
- 1198 [119] S.M. Hayes, E.W. Shores, P.E. Love, An architectural perspective on signaling by the
1199 pre-, $\alpha\beta$ and $\gamma\delta$ T cell receptors, *Immunol. Rev.* 191 (2003) 28–37.
1200 <https://doi.org/10.1034/j.1600-065X.2003.00011.x>.
- 1201 [120] S.M. Hayes, L. Li, P.E. Love, TCR signal strength influences $\alpha\beta/\gamma\delta$ lineage fate,
1202 *Immunity*. 22 (2005) 583–593. <https://doi.org/10.1016/j.immuni.2005.03.014>.
- 1203 [121] T. Kreslavsky, A.I. Garbe, A. Krueger, H. Von Boehmer, T cell receptor-instructed $\alpha\beta$
1204 versus $\gamma\delta$ lineage commitment revealed by single-cell analysis, *J. Exp. Med.* 205
1205 (2008) 1173–1186. <https://doi.org/10.1084/jem.20072425>.
- 1206 [122] P. Zarin, G.W. Wong, M. Mohtashami, D.L. Wiest, J.C. Zúñiga-Pflücker, Enforcement
1207 of $\gamma\delta$ -lineage commitment by the pre-T-cell receptor in precursors with weak $\gamma\delta$ -TCR
1208 signals, *Proc. Natl. Acad. Sci. U. S. A.* 111 (2014) 5658–5663.
1209 <https://doi.org/10.1073/pnas.1312872111>.
- 1210 [123] W. Swat, R. Xavier, A. Mizoguchi, E. Mizoguchi, J. Fredericks, K. Fujikawa, A.K.
1211 Bhan, F.W. Alt, Essential role for Vav1 in activation, but not development, of $\gamma\delta$ T
1212 cells, *Int. Immunol.* 15 (2003) 215–221. <https://doi.org/10.1093/intimm/dxg021>.
- 1213 [124] E. Aguado, S. Richelme, S. Nuñez-Cruz, A. Miazek, A.-M. Mura, M. Richelme, X.-J.
1214 Guo, D. Sainy, H.-T. He, B. Malissen, M. Malissen, Induction of T helper type 2
1215 immunity by a point mutation in the LAT adaptor, *Science* (80-.). 296 (2002) 2036–
1216 2040. <https://doi.org/10.1126/science.1069057>.
- 1217 [125] S. Nuñez-Cruz, E. Aguado, S. Richelme, B. Chetaille, A.-M. Mura, M. Richelme, L.

- 1218 Pouyet, E. Jouvin-Marche, L. Xerri, B. Malissen, M. Malissen, LAT regulates $\gamma\delta$ T
 1219 cell homeostasis and differentiation, *Nat. Immunol.* 4 (2003) 999–1008.
 1220 <https://doi.org/10.1038/ni977>.
- 1221 [126] C. Saint-Ruf, M. Panigada, O. Azogul, P. Debey, H. Von Boehmer, F. Grassi,
 1222 Different initiation of pre-TCR and $\gamma\delta$ TCR signalling, *Nature.* 406 (2000) 524–527.
 1223 <https://doi.org/10.1038/35020093>.
- 1224 [127] I. Aifantis, C. Borowski, F. Gounari, H.D. Lacorazza, J. Nikolich-Zugich, H. von
 1225 Boehmer, A critical role for the cytoplasmic tail of pT α in T lymphocyte development,
 1226 *Nat. Immunol.* 3 (2002) 483–488. <https://doi.org/10.1038/ni779>.
- 1227 [128] J.P.H. Lauritsen, M.C. Haks, J.M. Lefebvre, D.J. Kappes, D.L. Wiest, Recent insights
 1228 into the signals that control $\alpha\beta/\gamma\delta$ - lineage fate, *Immunol. Rev.* 209 (2006) 176–190.
 1229 <https://doi.org/10.1111/j.0105-2896.2006.00349.x>.
- 1230 [129] R.R. Rivera, C.P. Johns, J. Quan, R.S. Johnson, C. Murre, Thymocyte selection is
 1231 regulated by the helix-loop-helix inhibitor protein, Id3, *Immunity.* 12 (2000) 17–26.
 1232 [https://doi.org/10.1016/S1074-7613\(00\)80155-7](https://doi.org/10.1016/S1074-7613(00)80155-7).
- 1233 [130] I. Engel, C. Johns, G. Bain, R.R. Rivera, C. Murre, Early thymocyte development is
 1234 regulated by modulation of E2A protein activity, *J. Exp. Med.* 194 (2001) 733–745.
 1235 <https://doi.org/10.1084/jem.194.6.733>.
- 1236 [131] S.-Y. Lee, F. Coffey, S.P. Fahl, S. Peri, M. Rhodes, K.Q. Cai, M. Carleton, S.M.
 1237 Hedrick, H.J. Fehling, J.C. Zúñiga-Pflücker, D.J. Kappes, D.L. Wiest, Noncanonical
 1238 mode of ERK action controls alternative $\alpha\beta$ and $\gamma\delta$ T cell lineage fates, *Immunity.* 41
 1239 (2014) 934–946. <https://doi.org/10.1016/j.immuni.2014.10.021>.
- 1240 [132] L.O. Murphy, S. Smith, R.-H. Chen, D.C. Fingar, J. Blenis, Molecular interpretation of
 1241 ERK signal duration by immediate early gene products, *Nat. Cell Biol.* 4 (2002) 556–
 1242 564. <https://doi.org/10.1038/ncb822>.
- 1243 [133] L.O. Murphy, J. Blenis, MAPK signal specificity: the right place at the right time,
 1244 *Trends Biochem. Sci.* 31 (2006) 268–275. <https://doi.org/10.1016/j.tibs.2006.03.009>.
- 1245 [134] J. Roels, A. Kuchmiy, M. De Decker, S. Strubbe, M. Lavaert, K.L. Liang, G. Leclercq,
 1246 B. Vandekerckhove, F. Van Nieuwerburgh, P. Van Vlierberghe, T. Taghon, Distinct
 1247 and temporary-restricted epigenetic mechanisms regulate human $\alpha\beta$ and $\gamma\delta$ T cell
 1248 development, *Nat. Immunol.* 21 (2020) 1280–1292. <https://doi.org/10.1038/s41590-020-0747-9>.
- 1250 [135] J.-R. Hwang, Y. Byeon, D. Kim, S.-G. Park, Recent insights of T cell receptor-
 1251 mediated signaling pathways for T cell activation and development, *Exp. Mol. Med.*
 1252 52 (2020) 750–761. <https://doi.org/10.1038/s12276-020-0435-8>.
- 1253 [136] M. Yukawa, S. Jagannathan, S. Vallabh, A. V. Kartashov, X. Chen, M.T. Weirauch, A.
 1254 Barski, AP-1 activity induced by co-stimulation is required for chromatin opening
 1255 during T cell activation, *J. Exp. Med.* 217 (2020) e20182009.
 1256 https://doi.org/10.1084/jem_20182009.
- 1257 [137] M. De Smedt, K. Reynvoet, T. Kerre, T. Taghon, B. Verhasselt, B. Vandekerckhove,
 1258 G. Leclercq, J. Plum, Active Form of Notch Imposes T Cell Fate in Human Progenitor
 1259 Cells, *J. Immunol.* 169 (2002) 3021–3029.
 1260 <https://doi.org/10.4049/jimmunol.169.6.3021>.
- 1261 [138] A. Dolens, K. Durinck, M. Lavaert, J. Van der Meulen, I. Velghe, J. De Medts, K.

- 1262 Weening, J. Roels, K. De Mulder, P. Volders, K. De Preter, T. Kerre, B.
 1263 Vandekerckhove, G. Leclercq, J. Vandesompele, P. Mestdagh, P. Van Vlierberghe, F.
 1264 Speleman, T. Taghon, Distinct Notch1 and BCL11B requirements mediate human
 1265 $\gamma\delta/\alpha\beta$ T cell development, *EMBO Rep.* 21 (2020) e49006.
 1266 <https://doi.org/10.15252/embr.201949006>.
- 1267 [139] I. Van De Walle, G. De Smet, M. Gärtner, M. De Smedt, E. Waegemans, B.
 1268 Vandekerckhove, G. Leclercq, J. Plum, J.C. Aster, I.D. Bernstein, C.J. Gidos, B.
 1269 Kyewski, T. Taghon, Jagged2 acts as a Delta-like Notch ligand during early
 1270 hematopoietic cell fate decisions, *Blood.* 117 (2011) 4449–4459.
 1271 <https://doi.org/10.1182/blood-2010-06-290049>.
- 1272 [140] M.J. García-Leoń, P. Fuentes, J.L. De La Pompa, M.L. Toribio, Dynamic regulation of
 1273 NOTCH1 activation and Notch ligand expression in human thymus development,
 1274 *Development.* 145 (2018) dev165597. <https://doi.org/10.1242/dev.165597>.
- 1275 [141] T.A. Moore, U. Von Freeden-Jeffry, R. Murray, A. Zlotnik, Inhibition of $\gamma\delta$ T cell
 1276 development and early thymocyte maturation in IL-7 $-/-$ mice, *J. Immunol.* 157 (1996)
 1277 2366–73. <http://www.ncbi.nlm.nih.gov/pubmed/8805634>.
- 1278 [142] Y.-W. He, T.R. Malek, Interleukin-7 Receptor alpha is essential for the development
 1279 of $\gamma\delta^+$ T cells, but not for Natural Killer Cells, *J. Exp. Med.* 184 (1996) 289–293.
- 1280 [143] N. Aghaallaei, A.M. Dick, E. Tsingos, D. Inoue, E. Hasel, T. Thumberger, A. Toyoda,
 1281 M. Leptin, J. Wittbrodt, B. Bajoghli, $\alpha\beta/\gamma\delta$ T cell lineage outcome is regulated by
 1282 intrathymic cell localization and environmental signals, *Sci. Adv.* 7 (2021) eabg3613.
 1283 <https://doi.org/10.1126/sciadv.abg3613>.
- 1284 [144] D.-F. Lawir, I. Hess, K. Sikora, N. Iwanami, I. Siamishi, M. Schorpp, T. Boehm,
 1285 Evolutionary transition from degenerate to nonredundant cytokine signaling networks
 1286 supporting intrathymic T cell development, *Proc. Natl. Acad. Sci. U. S. A.* 116 (2019)
 1287 26759–26767. <https://doi.org/10.1073/pnas.1915223116>.
- 1288 [145] Y. Zeng, C. Liu, Y. Gong, Z. Bai, S. Hou, J. He, Z. Bian, Z. Li, Y. Ni, J. Yan, T.
 1289 Huang, H. Shi, C. Ma, X. Chen, J. Wang, L. Bian, Y. Lan, B. Liu, H. Hu, Single-Cell
 1290 RNA Sequencing Resolves Spatiotemporal Development of Pre-thymic Lymphoid
 1291 Progenitors and Thymus Organogenesis in Human Embryos, *Immunity.* 51 (2019)
 1292 930–948. <https://doi.org/10.1016/j.immuni.2019.09.008>.
- 1293 [146] A. Nicolae, L. Xi, S. Pittaluga, Z. Abdullaev, S.D. Pack, J. Chen, T.A. Waldmann, E.S.
 1294 Jaffe, M. Raffeld, Frequent STAT5B mutations in $\gamma\delta$ hepatosplenic T-cell lymphomas,
 1295 *Leukemia.* 28 (2014) 2244–2248. <https://doi.org/10.1038/leu.2014.200>.
- 1296 [147] C. Küçük, B. Jiang, X. Hu, W. Zhang, J.K.C. Chan, W. Xiao, N. Lack, C. Alkan, J.C.
 1297 Williams, K.N. Avery, P. Kavak, A. Scuto, E. Sen, P. Gaulard, L. Staudt, J. Iqbal, W.
 1298 Zhang, A. Cornish, Q. Gong, Q. Yang, H. Sun, F. D’Amore, S. Leppä, W. Liu, K. Fu,
 1299 L. De Leval, T. McKeithan, W.C. Chan, Activating mutations of STAT5B and STAT3
 1300 in lymphomas derived from $\gamma\delta$ -T or NK cells, *Nat. Commun.* 6 (2015) 1–12.
 1301 <https://doi.org/10.1038/ncomms7025>.
- 1302 [148] B. Silva-Santos, D.J. Pennington, A.C. Hayday, Lymphotoxin-mediated regulation of
 1303 $\gamma\delta$ cell differentiation by $\alpha\beta$ T cell progenitors, *Science* (80-.). 307 (2005) 925–928.
 1304 <https://doi.org/10.1126/science.1103978>.
- 1305 [149] B. Blom, M.H.M. Heemskerk, M.C.M. Verschuren, J.J.M. Van Dongen, A.P.A.
 1306 Stegmann, A.Q. Bakker, F. Couwenberg, P.C.M. Res, H. Spits, Disruption of $\alpha\beta$ but

- 1307 not of $\gamma\delta$ T cell development by overexpression of the helix-loop-helix protein Id3 in
 1308 committed T cell progenitors., *EMBO J.* 18 (1999) 2793–2802.
 1309 <https://doi.org/10.1093/EMBOJ/18.10.2793>.
- 1310 [150] M.H.M. Heemskerk, B. Blom, G. Nolan, A.P.A. Stegmann, A.Q. Bakker, K. Weijer,
 1311 P.C.M. Res, H. Spits, Inhibition of T cell and promotion of natural killer cell
 1312 development by the dominant negative helix loop helix factor Id3, *J. Exp. Med.* 186
 1313 (1997) 1597–1602. <https://doi.org/10.1084/jem.186.9.1597>.
- 1314 [151] T.S.H. In, A. Trotman-Grant, S. Fahl, E.L.Y. Chen, P. Zarin, A.J. Moore, D.L. Wiest,
 1315 J.C. Zúñiga-Pflücker, M.K. Anderson, HEB is required for the specification of fetal
 1316 IL-17-producing $\gamma\delta$ T cells, *Nat. Commun.* 8 (2017) 1–15.
 1317 <https://doi.org/10.1038/s41467-017-02225-5>.
- 1318 [152] J.P.H. Lauritsen, G.W. Wong, S.Y. Lee, J.M. Lefebvre, M. Ciofani, M. Rhodes, D.J.
 1319 Kappes, J.C. Zúñiga-Pflücker, D.L. Wiest, Marked Induction of the Helix-Loop-Helix
 1320 Protein Id3 Promotes the $\gamma\delta$ T Cell Fate and Renders Their Functional Maturation
 1321 Notch Independent, *Immunity.* 31 (2009) 565–575.
 1322 <https://doi.org/10.1016/j.immuni.2009.07.010>.
- 1323 [153] N. Malhotra, K. Narayan, O.H. Cho, K.E. Sylvia, C. Yin, H. Melichar, M. Rashighi, V.
 1324 Lefebvre, J.E. Harris, L.J. Berg, J. Kang, The Immunological Genome Project
 1325 Consortium, A network of high-mobility group box transcription factors programs
 1326 innate interleukin-17 production, *Immunity.* 38 (2013) 681–693.
 1327 <https://doi.org/10.1016/j.immuni.2013.01.010>.
- 1328 [154] E.E. Gray, F. Ramírez-Valle, Y. Xu, S. Wu, Z. Wu, K.E. Karjalainen, J.G. Cyster,
 1329 Deficiency in IL-17-committed $V\gamma 4+$ $\gamma\delta$ T cells in a spontaneous Sox13-mutant
 1330 CD45.1+ congenic mouse substrain provides protection from dermatitis, *Nat.*
 1331 *Immunol.* 14 (2013) 584–592. <https://doi.org/10.1038/ni.2585>.
- 1332 [155] J.E. Park, R.A. Botting, C.D. Conde, D.M. Popescu, M. Lavaert, D.J. Kunz, I. Goh, E.
 1333 Stephenson, R. Ragazzini, E. Tuck, A. Wilbrey-Clark, K. Roberts, V.R. Kedlian, J.R.
 1334 Ferdinand, X. He, S. Webb, D. Maunder, N. Vandamme, K.T. Mahbubani, K.
 1335 Polanski, L. Mamanova, L. Bolt, D. Crossland, F. De Rita, A. Fuller, A. Filby, G.
 1336 Reynolds, D. Dixon, K. Saeb-Parsy, S. Lisgo, D. Henderson, R. Vento-Tormo, O.A.
 1337 Bayraktar, R.A. Barker, K.B. Meyer, Y. Saeys, P. Bonfanti, S. Behjati, M.R.
 1338 Clatworthy, T. Taghon, M. Haniffa, S.A. Teichmann, A cell atlas of human thymic
 1339 development defines T cell repertoire formation, *Science* (80-.). 367 (2020).
 1340 <https://doi.org/10.1126/science.aay3224>.
- 1341 [156] R. Setoguchi, M. Tachibana, Y. Naoe, S. Muroi, K. Akiyama, C. Tezuka, T. Okuda, I.
 1342 Taniuchi, Repression of the transcription factor Th-POK by Runx complexes in
 1343 cytotoxic T cell development, *Science* (80-.). 319 (2008) 822–825.
 1344 <https://doi.org/10.1126/science.1151844>.
- 1345 [157] K. Narayan, K.E. Sylvia, N. Malhotra, C.C. Yin, G. Martens, T. Vallerskog, H.
 1346 Kornfeld, N. Xiong, N.R. Cohen, M.B. Brenner, L.J. Berg, J. Kang, The
 1347 Immunological Genome Project Consortium, Intrathymic programming of effector
 1348 fates in three molecularly distinct $\gamma\delta$ T cell subtypes, *Nat. Immunol.* 13 (2012) 511–
 1349 518. <https://doi.org/10.1038/ni.2247>.
- 1350 [158] Sagar, M. Pokrovskii, J.S. Herman, S. Naik, E. Sock, P. Zeis, U. Lausch, M. Wegner,
 1351 Y. Tanriver, D.R. Littman, D. Grün, Deciphering the regulatory landscape of fetal and
 1352 adult $\gamma\delta$ T-cell development at single-cell resolution, *EMBO J.* 39 (2020) 1–20.

- 1353 <https://doi.org/10.15252/emj.2019104159>.
- 1354 [159] Z. Yin, C. Chen, S.J. Szabo, L.H. Glimcher, A. Ray, J. Craft, T-Bet Expression and
1355 Failure of GATA-3 Cross-Regulation Lead to Default Production of IFN- γ by $\gamma\delta$ T
1356 Cells, *J. Immunol.* 168 (2002) 1566–1571.
1357 <https://doi.org/10.4049/jimmunol.168.4.1566>.
- 1358 [160] L. Chen, W. He, S.T. Kim, J. Tao, Y. Gao, H. Chi, A.M. Intlekofer, B. Harvey, S.L.
1359 Reiner, Z. Yin, R.A. Flavell, J. Craft, Epigenetic and Transcriptional Programs Lead to
1360 Default IFN- γ Production by $\gamma\delta$ T Cells, *J. Immunol.* 178 (2007) 2730–2736.
1361 <https://doi.org/10.4049/jimmunol.178.5.2730>.
- 1362 [161] J. Roels, M. Thénoz, B. Szarzyńska, M. Landfors, S. De Coninck, L. Demoen, L.
1363 Provez, A. Kuchmiy, S. Strubbe, L. Reunes, T. Pieters, F. Matthijssens, W. Van
1364 Loocke, B. Erarslan-Uysal, P. Richter-Pechańska, K. Declerck, T. Lammens, B. De
1365 Moerloose, D. Deforce, F. Van Nieuwerburgh, L.C. Cheung, R.S. Kotecha, M.R.
1366 Mansour, B. Ghesquière, G. Van Camp, W. Vanden Berghe, J.R. Kowalczyk, T.
1367 Szczepański, U.P. Davé, A.E. Kulozik, S. Goossens, D.J. Curtis, T. Taghon, M.
1368 Dawidowska, S. Degerman, P. Van Vlierberghe, Aging of Preleukemic Thymocytes
1369 Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia, *Blood*
1370 *Cancer Discov.* 1 (2020) 274–289. <https://doi.org/10.1158/2643-3230.bcd-20-0059>.
- 1371 [162] G. Gordino, S. Costa-Pereira, P. Corredeira, P. Alves, L. Costa, A.Q. Gomes, B. Silva-
1372 Santos, J.C. Ribot, MicroRNA-181a restricts human $\gamma\delta$ T cell differentiation by
1373 targeting Map3k2 and Notch2, *EMBO Rep.* 23 (2022) e52234.
1374 <https://doi.org/10.15252/embr.202052234>.
- 1375 [163] Y.R. Carrasco, C. Trigueros, A.R. Ramiro, V.G. De Yébenes, M.L. Toribio, β -
1376 Selection is associated with the onset of CD8 β chain expression on CD4 $^{+}$ CD8 $\alpha\alpha^{+}$
1377 pre-T cells during human intrathymic development, *Blood.* 94 (1999) 3491–3498.
1378 https://doi.org/10.1182/blood.v94.10.3491.422k30_3491_3498.
- 1379 [164] T. Taghon, I. De Van Walle, G. De Smet, M. De Smedt, G. Leclercq, B.
1380 Vandekerckhove, J. Plum, Notch signaling is required for proliferation but not for
1381 differentiation at a well-defined β -selection checkpoint during human T-cell
1382 development, *Blood.* 113 (2009) 3254–3263. [https://doi.org/10.1182/blood-2008-07-](https://doi.org/10.1182/blood-2008-07-168906)
1383 [168906](https://doi.org/10.1182/blood-2008-07-168906).
- 1384 [165] E.L.Y. Chen, P.M. Brauer, E.C. Martinez, X. Huang, N. Yu, M.K. Anderson, Y. Li,
1385 J.C. Zúñiga-pflücker, *J. Immunol.* E.L.Y. Chen, P.M. Brauer, E.C. Martinez, X.
1386 Huang, TCR- β Selection Is Required at the CD4 $^{+}$ CD8 $^{+}$ Stage of Human T Cell
1387 Development, *J. Immunol.* 206 (2021) 2271–2276.
1388 <https://doi.org/10.4049/jimmunol.2100141>.
- 1389 [166] H. Spits, Development of $\alpha\beta$ T cells in the human thymus, *Nat. Rev. Immunol.* 2
1390 (2002) 760–772. <https://doi.org/10.1038/nri913>.
- 1391 [167] M.S. Davey, C.R. Willcox, A.T. Baker, S. Hunter, B.E. Willcox, Recasting Human
1392 V δ 1 Lymphocytes in an Adaptive Role, *Trends Immunol.* 39 (2018) 446–459.
1393 <https://doi.org/10.1016/j.it.2018.03.003>.
- 1394 [168] L.M. Boyden, J.M. Lewis, S.D. Barbee, A. Bas, M. Girardi, A.C. Hayday, R.E.
1395 Tigelaar, R.P. Lifton, Skint1, the prototype of a newly identified immunoglobulin
1396 superfamily gene cluster, positively selects epidermal $\gamma\delta$ T cells, *Nat. Genet.* 40 (2008)
1397 656–662. <https://doi.org/10.1038/ng.108>.

- 1398 [169] S.D. Barbee, M.J. Woodward, G. Turchinovich, J.-J. Mention, J.M. Lewis, L.M.
 1399 Boyden, R.P. Lifton, R. Tigelaar, A.C. Hayday, Skint-1 is a highly specific, unique
 1400 selecting component for epidermal T cells, *Proc. Natl. Acad. Sci. U. S. A.* 108 (2011)
 1401 3330–3335. <https://doi.org/10.1073/pnas.1010890108>.
- 1402 [170] T. Dimova, M. Brouwer, F. Gosselin, J. Tassignon, O. Leo, C. Donner, A. Marchant,
 1403 D. Vermijlen, Effector V γ 9V δ 2 t cells dominate the human fetal $\gamma\delta$ T-cell repertoire,
 1404 *Proc. Natl. Acad. Sci. U. S. A.* 112 (2015) E556–E565.
 1405 <https://doi.org/10.1073/pnas.1412058112>.
- 1406 [171] K.D.C. Jensen, X. Su, S. Shin, L. Li, S. Youssef, S. Yamasaki, L. Steinman, T. Saito,
 1407 R.M. Locksley, M.M. Davis, N. Baumgarth, Y. Chien, Thymic Selection Determines
 1408 $\gamma\delta$ T Cell Effector Fate: Antigen-Naive Cells Make Interleukin-17 and Antigen-
 1409 Experienced Cells Make Interferon γ , *Immunity*. 29 (2008) 90–100.
 1410 <https://doi.org/10.1016/j.immuni.2008.04.022>.
- 1411 [172] C. Meyer, X. Zeng, Y. Chien, Ligand recognition during thymic development and $\gamma\delta$ T
 1412 cell function specification, *Semin. Immunol.* 22 (2010) 207–213.
 1413 <https://doi.org/10.1016/j.smim.2010.04.002.Ligand>.
- 1414 [173] F. Deknuydt, E. Scotet, M. Bonneville, Modulation of inflammation through IL-17
 1415 production by $\gamma\delta$ T cells: Mandatory in the mouse, dispensable in humans?, *Immunol.*
 1416 *Lett.* 127 (2009) 8–12. <https://doi.org/10.1016/j.imlet.2009.08.003>.
- 1417 [174] F. Coffey, S.-Y. Lee, T.B. Buus, J.P.H. Lauritsen, G.W. Wong, M.L. Joachims, L.F.
 1418 Thompson, J.C. Zúñiga-Pflücker, D.J. Kappes, D.L. Wiest, The TCR ligand-inducible
 1419 expression of CD73 marks $\gamma\delta$ lineage commitment and a metastable intermediate in
 1420 effector specification, *J. Exp. Med.* 211 (2014) 329–343.
 1421 <https://doi.org/10.1084/jem.20131540>.
- 1422 [175] Y. Jouan, E.C. Patin, M. Hassane, M. Si-Tahar, T. Baranek, C. Paget, Thymic program
 1423 directing the functional development of $\gamma\delta$ T17 Cells, *Front. Immunol.* 9 (2018) 981.
 1424 <https://doi.org/10.3389/fimmu.2018.00981>.
- 1425 [176] J.C. Ribot, A. deBarros, D.J. Pang, J.F. Neves, V. Peperzak, S.J. Roberts, M. Girardi,
 1426 J. Borst, A.C. Hayday, D.J. Pennington, B. Silva-Santos, CD27 is a thymic
 1427 determinant of the balance between interferon- γ - and interleukin 17-producing $\gamma\delta$ T
 1428 cell subsets, *Nat. Immunol.* 10 (2009) 427–436. <https://doi.org/10.1038/ni.1717>.
- 1429 [177] M. Munoz-Ruiz, J.C. Ribot, A.R. Grosso, N. Goncalves-Sousa, A. Pamplona, D.J.
 1430 Pennington, J.R. Regueiro, E. Fernandez-Malavé, B. Silva-Santos, TCR signal strength
 1431 controls thymic differentiation of discrete proinflammatory $\gamma\delta$ T cell subsets, *Nat.*
 1432 *Immunol.* 17 (2016) 721–727. <https://doi.org/10.1038/ni.3424>.
- 1433 [178] D. Fenoglio, A. Poggi, S. Catellani, F. Battaglia, A. Ferrera, M. Setti, G. Murdaca,
 1434 M.R. Zocchi, V δ 1 T lymphocytes producing IFN- γ and IL-17 are expanded in HIV-1-
 1435 infected patients and respond to *Candida albicans*, *Blood*. 113 (2009) 6611–6618.
 1436 <https://doi.org/10.1182/blood-2009-01-198028>.
- 1437 [179] M. Peng, Z. Wang, C. Yao, L. Jiang, Q. Jin, J. Wang, B. Li, Interleukin 17-producing
 1438 $\gamma\delta$ T cells increased in patients with active pulmonary tuberculosis, *Cell. Mol.*
 1439 *Immunol.* 5 (2008) 203–208. <https://doi.org/10.1038/cmi.2008.25>.
- 1440 [180] J.C. Ribot, S.T. Ribeiro, D. V. Correia, A.E. Sousa, B. Silva-Santos, Human $\gamma\delta$
 1441 Thymocytes Are Functionally Immature and Differentiate into Cytotoxic Type 1
 1442 Effector T Cells upon IL-2/IL-15 Signaling, *J. Immunol.* 192 (2014) 2237–2243.

- 1443 <https://doi.org/10.4049/jimmunol.1303119>.
- 1444 [181] M.L. Michel, D.J. Pang, S.F.Y. Haque, A.J. Potocnik, D.J. Pennington, A.C. Hayday,
1445 Interleukin 7 (IL-7) selectively promotes mouse and human IL-17-producing $\gamma\delta$ cells,
1446 Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 17549–17554.
1447 <https://doi.org/10.1073/pnas.1204327109>.
- 1448 [182] L. Tan, A.S. Fichtner, E. Bruni, I. Odak, I. Sandrock, A. Bubke, A. Borchers, C.
1449 Schultze-Florey, C. Koenecke, R. Förster, M. Jarek, C. Von Kaisenberg, A. Schulz, X.
1450 Chu, B. Zhang, Y. Li, U. Panzer, C.F. Krebs, S. Ravens, I. Prinz, A fetal wave of
1451 human type 3 effector $\gamma\delta$ cells with restricted TCR diversity persists into adulthood,
1452 Sci. Immunol. 6 (2021) eabf0125. <https://doi.org/10.1126/sciimmunol.abf0125>.
- 1453 [183] G.S. Sanchez, M. Papadopoulou, A. Abdulkader, Y. Tafesse, A. Mishra, J.K.Y. Chan,
1454 Y. Fan, I. Verdebout, S. Porco, F. Libert, F. Ginhoux, B. Vandekerckhove, S. Goriely,
1455 D. Vermijlen, Identification of distinct functional thymic programming of fetal and
1456 pediatric human $\gamma\delta$ thymocytes via single-cell analysis, Nat. Commun. 13 (2022) 5842.
- 1457 [184] M.S. Davey, C.R. Willcox, S. Hunter, Y.H. Oo, B.E. Willcox, $V\delta 2$ +T cells - Two
1458 subsets for the price of one, Front. Immunol. 9 (2018) 2106.
1459 <https://doi.org/10.3389/fimmu.2018.02106>.
- 1460 [185] D. Vermijlen, I. Prinz, Ontogeny of innate T lymphocytes - some innate lymphocytes
1461 are more innate than others, Front. Immunol. 5 (2014) 1–12.
1462 <https://doi.org/10.3389/fimmu.2014.00486>.
- 1463 [186] L. McVay, S. Carding, Extrathymic origin of human $\gamma\delta$ T cells during fetal
1464 development, J. Immunol. 157 (1996) 2873–82.
1465 <http://www.ncbi.nlm.nih.gov/pubmed/8816392>.
- 1466 [187] L.D. McVay, S.S. Jaswal, C. Kennedy, A. Hayday, S.R. Carding, The generation of
1467 human $\gamma\delta$ T cell repertoires during fetal development, J. Immunol. 160 (1998) 5851–
1468 60. <http://www.ncbi.nlm.nih.gov/pubmed/9637496>.
- 1469 [188] C.T. Morita, C.M. Parker, M.B. Brenner, H. Band, TCR usage and functional
1470 capabilities of human gamma delta T cells at birth, J. Immunol. 153 (1994) 3979–88.
1471 <http://www.ncbi.nlm.nih.gov/pubmed/7930606>.
- 1472 [189] C.M. Parker, V. Groh, H. Band, S.A. Porcelli, C. Morita, M. Fabbi, D. Glass, J.L.
1473 Strominger, M.B. Brenner, Evidence for extrathymic changes in the T cell receptor $\gamma\delta$
1474 repertoire, J. Exp. Med. 171 (1990) 1597–1612.
1475 <https://doi.org/10.1084/jem.171.5.1597>.
- 1476 [190] M. Papadopoulou, T. Dimova, M. Shey, L. Briel, H. Veldtsman, N. Khomba, H.
1477 Africa, M. Steyne, W.A. Hanekom, T.J. Scriba, E. Nemes, D. Vermijlen, Fetal public
1478 $V\gamma 9V\delta 2$ T cells expand and gain potent cytotoxic functions early after birth, Proc.
1479 Natl. Acad. Sci. U. S. A. 117 (2020) 18638–18648.
1480 <https://doi.org/10.1073/pnas.1922595117>.
- 1481 [191] F. Davodeau, M.A. Peyrat, M.M. Hallet, I. Houde, H. Vie, M. Bonneville, Peripheral
1482 selection of antigen receptor junctional features in a major human $\gamma\delta$ subset, Eur J
1483 Immunol. 23 (1993) 804–808.
- 1484 [192] G. De Libero, G. Casorati, C. Giachino, C. Carbonara, N. Migone, P. Matzinger, A.
1485 Lanzavecchia, Selection by two powerful antigens may account for the presence of the
1486 major population of human peripheral $\gamma\delta$ T cells, J. Exp. Med. 173 (1991) 1311–1322.
1487 <https://doi.org/10.1084/jem.173.6.1311>.

- 1488 [193] S. Ravens, A.S. Fichtner, M. Willers, D. Torkornoo, S. Pirr, J. Schöning, M. Deseke, I.
1489 Sandrock, A. Bubke, A. Wilharm, D. Dodoo, B. Egyir, K.L. Flanagan, L. Steinbrück,
1490 P. Dickinson, P. Ghazal, B. Adu, D. Viemann, I. Prinz, Microbial exposure drives
1491 polyclonal expansion of innate $\gamma\delta$ T cells immediately after birth, *Proc. Natl. Acad.*
1492 *Sci. U. S. A.* 117 (2020) 18649–18660. <https://doi.org/10.1073/pnas.1922588117>.
- 1493 [194] M. Hirokawa, T. Horiuchi, Y. Kawabata, A. Kitabayashi, A.B. Miura, Reconstitution
1494 of $\gamma\delta$ T cell repertoire diversity after human allogeneic hematopoietic cell
1495 transplantation and the role of peripheral expansion of mature T cell population in the
1496 graft, *Bone Marrow Transplant.* 26 (2000) 177–185.
1497 <https://doi.org/10.1038/sj.bmt.1702478>.
- 1498 [195] S. Ravens, C. Schultze-Florey, S. Raha, I. Sandrock, M. Drenker, L. Oberdörfer, A.
1499 Reinhardt, I. Ravens, M. Beck, R. Geffers, C. Von Kaisenberg, M. Heuser, F. Thol, A.
1500 Ganser, R. Förster, C. Koenecke, I. Prinz, Human $\gamma\delta$ T cells are quickly reconstituted
1501 after stem-cell transplantation and show adaptive clonal expansion in response to viral
1502 infection, *Nat. Immunol.* 18 (2017) 393–401. <https://doi.org/10.1038/ni.3686>.
- 1503 [196] M.S. Davey, C.R. Willcox, S. Hunter, S.A. Kasatskaya, E.B.M. Remmerswaal, M.
1504 Salim, F. Mohammed, F.J. Bemelman, D.M. Chudakov, Y.H. Oo, B.E. Willcox, The
1505 human $V\delta 2+$ T-cell compartment comprises distinct innate-like $V\gamma 9+$ and adaptive
1506 $V\gamma 9-$ subsets, *Nat. Commun.* 9 (2018) 1–14. [https://doi.org/10.1038/s41467-018-](https://doi.org/10.1038/s41467-018-04076-0)
1507 [04076-0](https://doi.org/10.1038/s41467-018-04076-0).
- 1508 [197] D. Vermijlen, M. Brouwer, C. Donner, C. Liesnard, M. Tackoen, M. Van Rysselberge,
1509 N. Twité, M. Goldman, A. Marchant, F. Willems, Human cytomegalovirus elicits fetal
1510 $\gamma\delta$ T cell responses in utero, *J. Exp. Med.* 207 (2010) 807–821.
1511 <https://doi.org/10.1084/jem.20090348>.
- 1512 [198] B.L. Clark, P.G. Thomas, A cell for the ages: Human $\gamma\delta$ T cells across the lifespan, *Int.*
1513 *J. Mol. Sci.* 21 (2020) 1–18. <https://doi.org/10.3390/ijms21238903>.
- 1514 [199] J. Daniels, P.G. Doukas, M.E. Martinez Escala, K.G. Ringbloom, D.J.H. Shih, J. Yang,
1515 K. Tegtmeyer, J. Park, J.J. Thomas, M.E. Selli, C. Altunbulakli, R. Gowthaman, S.H.
1516 Mo, B. Jothishankar, D.R. Pease, B. Pro, F.R. Abdulla, C. Shea, N. Sahni, A.A. Gru,
1517 B.G. Pierce, A. Louissaint Jr, J. Guitart, J. Choi, Cellular origins and genetic landscape
1518 of cutaneous gamma delta T cell lymphomas, *Nat. Commun.* 11 (2020) 1–14.
1519 <https://doi.org/10.1038/s41467-020-15572-7>.
- 1520 [200] M. van der Heiden, S. Björkander, K. Rahman Qazi, J. Bittmann, L. Hell, M.C.
1521 Jenmalm, G. Marchini, D. Vermijlen, T. Abrahamsson, C. Nilsson, E. Sverremark-
1522 Ekström, Characterization of the $\gamma\delta$ T-cell compartment during infancy reveals clear
1523 differences between the early neonatal period and 2 years of age, *Immunol. Cell Biol.*
1524 98 (2020) 79–87. <https://doi.org/10.1111/imcb.12303>.
- 1525 [201] E.L.Y. Chen, C.R. Lee, P.K. Thompson, D.L. Wiest, M.K. Anderson, J.C. Zúñiga-
1526 Pflücker, Ontogenic timing, T cell receptor signal strength, and Notch signaling direct
1527 $\gamma\delta$ T cell functional differentiation in vivo, *Cell Rep.* 35 (2021) 109227.
1528 <https://doi.org/10.1016/j.celrep.2021.109227>.
- 1529 [202] E.J. Adams, S. Gu, A.M. Luoma, Human gamma delta T cells: Evolution and ligand
1530 recognition, *Cell. Immunol.* 296 (2015) 31–40.
1531 <https://doi.org/10.1016/j.cellimm.2015.04.008>.
- 1532 [203] C.D. Castro, C.T. Boughter, A.E. Broughton, A. Ramesh, E.J. Adams, Diversity in
1533 recognition and function of human $\gamma\delta$ T cells, *Immunol. Rev.* 298 (2020) 134–152.

- 1534 <https://doi.org/10.1111/imr.12930>.
- 1535 [204] E.C. Dudley, H.T. Petrie, L.M. Shah, M.J. Owen, A.C. Hayday, T cell receptor β chain
1536 gene rearrangement and selection during thymocyte development in adult mice,
1537 *Immunity*. 1 (1994) 83–93. [https://doi.org/10.1016/1074-7613\(94\)90102-3](https://doi.org/10.1016/1074-7613(94)90102-3).
- 1538 [205] E.C. Dudley, M. Girardi, M.J. Owen, A.C. Hayday, $\alpha\beta$ and $\gamma\delta$ T cells can share a late
1539 common precursor, *Curr. Biol.* 5 (1995) 659–669. [https://doi.org/10.1016/S0960-9822\(95\)00131-X](https://doi.org/10.1016/S0960-9822(95)00131-X).
- 1541 [206] D.B. Burtrum, S. Kim, E.C. Dudley, A.C. Hayday, H.T. Petrie, TCR gene
1542 recombination and $\alpha\beta$ - $\gamma\delta$ lineage divergence: productive TCR- β rearrangement is
1543 neither exclusive nor preclusive of $\gamma\delta$ cell development, *J. Immunol.* 157 (1996) 4293–
1544 4296.
- 1545 [207] M. Ciofani, G.C. Knowles, D.L. Wiest, H. von Boehmer, J.C. Zúñiga-Pflücker, Stage-
1546 Specific and Differential Notch Dependency at the $\alpha\beta$ and $\gamma\delta$ T Lineage Bifurcation,
1547 *Immunity*. 25 (2006) 105–116. <https://doi.org/10.1016/j.immuni.2006.05.010>.
- 1548 [208] T. Taghon, M.A. Yui, R. Pant, R.A. Diamond, E. V. Rothenberg, Developmental and
1549 molecular characterization of emerging β - and $\gamma\delta$ -selected pre-T cells in the adult
1550 mouse thymus, *Immunity*. 24 (2006) 53–64.
1551 <https://doi.org/10.1016/j.immuni.2005.11.012>.
- 1552 [209] T. Washburn, E. Schweighoffer, T. Gridley, D. Chang, B.J. Fowlkes, D. Cado, E.
1553 Robey, Notch activity influences the $\alpha\beta$ versus $\gamma\delta$ T cell lineage decision, *Cell*. 88
1554 (1997) 833–843. [https://doi.org/10.1016/S0092-8674\(00\)81929-7](https://doi.org/10.1016/S0092-8674(00)81929-7).
- 1555 [210] J. Plum, M. De Smedt, G. Leclercq, Exogenous IL-7 promotes the growth of CD3-
1556 CD4-CD8-CD44+CD25+/- precursor cells and blocks the differentiation pathway of
1557 TCR- $\alpha\beta$ cells in fetal thymus organ culture, *J. Immunol.* 150 (1993) 2706–2716.
- 1558 [211] G.M. Siegers, M. Swamy, E. Fernández-Malavé, S. Minguet, S. Rathmann, A.C.
1559 Guardo, V. Pérez-Flores, J.R. Regueiro, B. Alarcón, P. Fisch, W.W.A. Schamel,
1560 Different composition of the human and the mouse $\gamma\delta$ T cell receptor explains different
1561 phenotypes of CD3 γ and CD3 δ immunodeficiencies, *J. Exp. Med.* 204 (2007) 2537–
1562 2544. <https://doi.org/10.1084/jem.20070782>.
- 1563 [212] M.C. Haks, P. Krimpenfort, J. Borst, A.M. Kruisbeek, The CD3 γ chain is essential for
1564 development of both the TCR $\alpha\beta$ and TCR $\gamma\delta$ lineages, *EMBO J.* 17 (1998) 1871–1882.
1565 <https://doi.org/10.1093/emboj/17.7.1871>.
- 1566 [213] M. Malissen, A. Gillet, L. Ardouin, G. Bouvier, J. Trucy, P. Ferrier, E. Vivier, B.
1567 Malissen, Altered T cell development in mice with a targeted mutation of the CD3- ϵ
1568 gene., *EMBO J.* 14 (1995) 4641–4653. <https://doi.org/10.1002/j.1460-2075.1995.tb00146.x>.
- 1570 [214] J.B. DeJarnette, C.L. Sommers, K. Huang, K.J. Woodside, R. Emmons, K. Katz, E.W.
1571 Shores, P.E. Love, Specific requirement for CD3 ϵ in T cell development, *Proc. Natl.*
1572 *Acad. Sci. U. S. A.* 95 (1998) 14909–14914. <https://doi.org/10.1073/pnas.95.25.14909>.
- 1573 [215] V.P. Dave, Z. Cao, C. Browne, B. Alarcon, G. Fernandez-Miguel, J. Lafaille, A. De La
1574 Hera, S. Tonegawa, D.J. Kappes, CD3 δ deficiency arrests development of the $\alpha\beta$ but
1575 not the $\gamma\delta$ T cell lineage, *EMBO J.* 16 (1997) 1360–1370.
1576 <https://doi.org/10.1093/emboj/16.6.1360>.
- 1577 [216] D.J. Pang, J.F. Neves, N. Sumaria, D.J. Pennington, Understanding the complexity of

- 1578 $\gamma\delta$ T-cell subsets in mouse and human, *Immunology*. 136 (2012) 283–290.
1579 <https://doi.org/10.1111/j.1365-2567.2012.03582.x>.
- 1580 [217] W.L. Havran, S. Grell, G. Duwe, J. Kimura, A. Wilson, A.M. Kruisbeek, R.L.
1581 O'Brien, W. Born, R.E. Tigelaar, J.P. Allison, Limited diversity of T-cell receptor γ -
1582 chain expression of murine Thy-1+ dendritic epidermal cells revealed by V γ 3-specific
1583 monoclonal antibody, *Proc. Natl. Acad. Sci. U. S. A.* 86 (1989) 4185–4189.
1584 <https://doi.org/10.1073/pnas.86.11.4185>.
- 1585 [218] J.D. Haas, S. Ravens, S. Düber, I. Sandrock, L. Oberdörfer, E. Kashani, V.
1586 Chennupati, L. Föhse, R. Naumann, S. Weiss, A. Krueger, R. Förster, I. Prinz,
1587 Development of Interleukin-17-Producing $\gamma\delta$ T Cells Is Restricted to a Functional
1588 Embryonic Wave, *Immunity*. 37 (2012) 48–59.
1589 <https://doi.org/10.1016/j.immuni.2012.06.003>.
- 1590 [219] N. Caccamo, C. La Mendola, V. Orlando, S. Meraviglia, M. Todaro, G. Stassi, G.
1591 Sireci, J.J. Fournie, F. Dieli, Differentiation, phenotype, and function of interleukin-
1592 17-producing human V γ 9V δ 2 T cells, *Blood*. 118 (2011) 129–138.
1593 <https://doi.org/10.1182/blood-2011-01-331298.An>.
- 1594
1595

1596 **Figure 1: T cell development in the human thymus**

1597 Schematic representation of human thymocyte differentiation. The main developmental
1598 stages are depicted and the timing of T lineage commitment and β -selection are indicated.
1599 The expression of key surface markers, receptors and rearrangement windows of the TCR
1600 genes are shown below, whereby green corresponds to bipotent cells, blue to the $\gamma\delta$ lineage
1601 and yellow to the $\alpha\beta$ lineage. Dashed colouring implies selective expression of the gene in
1602 either CD4+ or CD8+ SP thymocytes. The arrow thickness represents the assumed potential
1603 of thymocytes to differentiate along the $\alpha\beta$ or $\gamma\delta$ lineage; for further details on this also refer
1604 to section 3.2. HSPCs and TSPs are marked by the expression of CD34 but lack of CD1,
1605 whereas ETPs are characterised by the additional upregulation of CD7. The initiation of CD1
1606 expression and a decrease in CD44 levels signifies the commitment to the T lineage. CD4+
1607 ISP thymocytes show a gradual reduction in $\gamma\delta$ lineage potential and their maturation is
1608 associated with loss of CD34 expression and upregulation of CD28. The subsequent DP
1609 stage, during which the *TRA* locus is rearranged, can be divided into early (CD3-,
1610 proliferating) and late (CD3+, quiescent) DP thymocytes, which then further differentiate into
1611 either CD4+ or CD8+ SP cells. In the $\gamma\delta$ lineage, commitment to the $\gamma\delta$ fate is marked by the
1612 induction of CD73 and their subsequent maturation is indicated by downregulation of CD1
1613 and upregulation of CD27. Abbreviations: HSPC: Hematopoietic stem and progenitor cell,
1614 TSP: thymus seeding progenitor, ETP: early T cell progenitor, DC: Dendritic Cell, NK cell:
1615 Natural Killer Cell, ISP: Immature Single Positive, DP: Double Positive, SP: Single Positive,
1616 TRA/B/G/D: T cell receptor $\alpha/\beta/\gamma/\delta$ locus.

1617

1618 **Figure 2: Signalling pathways during $\gamma\delta$ T cell development**

1619 Schematic depiction of Notch, IL7R and TCR signalling at different stages of thymocyte
1620 differentiation. The direct and indirect effects of signalling activity on gene expression,
1621 V(D)J recombination, and viability are indicated. Of note, some of these mechanisms have
1622 only been reported in mouse thymocytes and are not yet confirmed in human. Abbreviations:
1623 TSP: thymus seeding progenitor, ETP: early T cell progenitor, ICN: intracellular domain of
1624 Notch, TCR: T cell receptor, TRG/D: T cell receptor γ/δ locus.

1625

1626 **Figure 3: The human *TRD* and *TRG* loci**

1627 Illustration of the structure of the human *TRD* and *TRG* loci (not to scale). Variable (V),
1628 diversity (D), joining (J) and constant (C) segments as well as the main enhancers (E δ and
1629 E γ) are shown. The *TRD* locus is nested within the *TRA* locus and several V-segments are
1630 shared between both genes. Interspersed *TRAV* segments are not depicted but their location
1631 has been indicated by dotted lines. Unfilled segments represent pseudogenes according to
1632 [202]. At the *TRD* locus, the *TRDV3* segment exhibits an inverted orientation as implied by
1633 the arrow. Certain V(D)J rearrangements predominantly take place during specific gestational
1634 windows, which are depicted below each locus. Of note, the constant segments do not
1635 undergo V(D)J recombination but are included during transcription and joined with the
1636 rearranged V(D)J segments via mRNA splicing. In this context, *TRGC1* is mainly used
1637 during early gestation, whereas *TRGC2* predominates in later development. Furthermore,

1638 during rearrangement of the *TRD* locus, two *TRDD* segments can be joined to a *TRDJ*
1639 segment, which further helps to increase the δ -chain diversity.

1640

1641 **Figure 4: Proportions of different human $\gamma\delta$ T cell subsets in thymus and blood**
1642 **throughout development**

1643 Overview of the frequencies of certain $\gamma\delta$ T cell subsets throughout gestation, shown as
1644 proportion of total $\gamma\delta$ T cells. Frequencies were gathered from a range of sources [54,55,186–
1645 190,200], which reported on embryonic, mid-gestation fetal, neonatal and paediatric thymus
1646 samples and cord or peripheral blood samples from mid-/late-gestation fetal, neonatal and
1647 paediatric donors.

1648



Feature	Mouse	Human
<i>TRGV</i> conservation	No phylogenetic homology [203]	
<i>TRD</i> locus conservation	Some sequence conservation but no evidence for functional similarities [203]	
Timing of <i>TRB</i> and <i>TRG</i> rearrangement	A notable proportion of thymic $\gamma\delta$ T cells have complete <i>Trb</i> rearrangements, suggesting parallel rearrangement of <i>Trb</i> and <i>Trg</i> [204–206]	Most thymic and peripheral $\alpha\beta$ T cells carry a rearranged <i>TRG</i> locus, but only a minor fraction of $\gamma\delta$ T cells/thymocytes have a rearranged <i>TRB</i> locus [49–51]
Allelic exclusion	Yes for <i>Trg</i> , no for <i>Trd</i> [64–66]	Yes for <i>TRD</i> , no for <i>TRG</i> [50,53,58–60]
Notch activity	Increase up until β -selection [112,207,208]	Decrease from T cell commitment onwards [101]
Notch requirement	$\alpha\beta$ lineage development depends on Notch signalling, whereas in $\gamma\delta$ lineage Notch is just needed for proliferation [112,207–209]	High Notch signalling promotes $\gamma\delta$ lineage, whereas $\alpha\beta$ lineage development requires Notch signalling reduction [33,39,41,101,137,138]
JAG2 expression	High in cortex, lower at cortico-medullary junction (CMJ) [140]	High at CMJ, lower in cortex [140]
IL7 in the fate decision	Impairment of IL7 signalling affects $\gamma\delta$ lineage severely but has little impact on $\alpha\beta$ lineage [141,142,210]	Contradicting findings, see section 3.1.3
Pre-programming of $\gamma\delta$ fate	IL7R/SOX13-high DN3s are biased towards $\gamma\delta$ lineage [116–118]	No evidence for pre-programming
TCR $\gamma\delta$ + DP3s	Have been observed in transgenic mice [112,113] but do not seem to arise during normal development	$\gamma\delta$ T cells can go through a DP3 stage under physiological conditions [114,115]
$\gamma\delta$ TCR complex stoichiometry	TCR $\gamma\delta$ + 2x CD3 $\gamma\epsilon$ + 2x TCR ζ [211]	TCR $\gamma\delta$ + 1x CD3 $\gamma\epsilon$ + 1x CD3 $\delta\epsilon$ + 2x TCR ζ [211]
Requirement of CD3 δ	$\gamma\delta$ T cells develop normally in CD3 δ deficient mice but knock-out of CD3 γ or CD3 ϵ affects $\alpha\beta$ and $\gamma\delta$ T cells [212–215]	Patients with CD3 δ deficiency don't have $\gamma\delta$ T cells but those with CD3 γ deficiency do, i.e. CD3 δ is required and can substitute for CD3 γ [211]
Fate decision point	Lineage decision is probably completed by the DN3 stage [121,207]	Cells retain $\gamma\delta$ potential up until DP3 stage [49,115]

CD27	Identifies $\gamma\delta$ T1 committed cells [176]	Identifies naïve V γ 9+V δ 2+ cells [216]
Effector specification in the thymus	Specification of IFN γ and IL17 producing subsets [157,171,175–177]	Some degree of effector programming in the fetal thymus [54,182,183]
IL7 in effector programming	Essential role of IL7 in effector differentiation [181]	Does not result in effector differentiation in the thymus [180]
Distinguishing feature of subtypes	<i>Trgv</i> [203]	<i>TRDV</i> [203]
Phosphoantigen-reactive $\gamma\delta$ T cells	Do not exist [185]	V γ 9+V δ 2+ subtype
Dendritic epidermal T cells (DETCs)	Epidermis-colonising subset with invariant $\gamma\delta$ TCR, which is the first subset to arise in the fetal thymus [217]	No equivalent subtype
Occurrence of IL17 producing $\gamma\delta$ T cells	Physiological subset, which is programmed in the thymus [153,175,181]	Can develop under pathological conditions in the periphery [178,179]
TCR composition of IL17-producing $\gamma\delta$ T cells	IL17-producing $\gamma\delta$ T cells display preferential use of certain <i>TRGV</i> elements [218]	IL17 production is found in both V δ 1 and V δ 2+ $\gamma\delta$ T cells [178,219]


1649

1650 **Table 1: Non-exhaustive list of differences between mouse and human in the context of**
1651 **$\gamma\delta$ T cell development in the thymus**


1652




TSP/ETP




TCR rearrangement




$\gamma\delta$ commitment



TRD (chr 14, + strand)



TRG (chr 7, - strand)







Figure 1




Figure 2




Figure 3




Figure 4

